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ABSTRACT 
Bhavna Choudhury 
 
SIBIOS AS A FRAMEWORK FOR BIOMARKER DISCOVERY USING 
MICROARRAY DATA 
 
Decoding the human genome resulted in generating large amount of data that need to be 
analyzed and given a biological meaning. The field of Life Sciences is highly information 
driven. The genomic data are mainly the gene expression data that are obtained from 
measurement of mRNA levels in an organism. Efficiently processing large amount of 
gene expression data has been possible with the help of high throughput technology. 
Research studies working on microarray data has led to the possibility of finding disease 
biomarkers. Carrying out biomarker discovery experiments has been greatly facilitated 
with the emergence of various analytical and visualization tools as well as annotation 
databases. These tools and databases are often termed as bioinformatics services. 
 
The main purpose of this research was to develop SIBIOS (System for Integration of 
Bioinformatics Services) as a platform to carry out microarray experiments for the 
purpose of biomarker discovery. Such experiments require the understanding of the 
current procedures adopted by researchers to extract biologically significant genes. 
 
In the course of this study, sample protocols were built for the purpose of biomarker 
discovery. A case study on the BCR-ABL subtype of ALL was selected to validate the 
  x
results. Different approaches for biomarker discovery were explored and both statistical 
and mining techniques were considered. Biological annotation of the results was also 
carried out. The final task was to incorporate the new proposed sample protocols into 
SIBIOS by providing the workflow capabilities and therefore enhancing the system's 
characteristics to be able to support biomarker discovery workflows. 
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1. INTRODUCTION 
 
1.1. Importance of Biomarkers 
 
Every human cell consists of a nucleus which is a storehouse of the chromosome, containing 
the genetic code i.e. DNA (Deoxyribonucleic Acid). The biological human functions are 
based on the code read from the DNA. DNAs are large doubly stranded structures that 
contain thousands of genes. DNA maps to mRNAs which eventually code for proteins which 
have a certain structure and function. It is considered normal if the mappings between the 
mRNA and proteins are coded properly. The level of mRNA produced, which in turn 
controls the protein production, corresponds to what is called gene expression. Typically, 
mutations or abnormal coding in the DNA can cause variations in the gene-expression levels 
making it either up-regulated or down-regulated compared to the normal gene.  These 
changes also affect the protein levels in the body. These global expression patterns that allow 
us to understand gene-gene interaction networks can be monitored by microarrays.  
 
Differentially expressed genes and proteins in tumor cells can be identified using approaches 
like genomics, transcriptomics and proteomics. These are the available technologies and 
resources that empower the process to identify significant genes.  
 
Recently, with the advent of microarray global technology for DNA (1990), it is possible to 
measure RNA expression levels with extreme ease and precision. DNA microarrays are 
useful for assessing the expression of mRNAs from a set of biological samples. Gene 
  2 
expression analysis can contain large amounts of information related to the DNA sequence, 
state of the cell, biological phenomena like cell growth and development, disease progression 
etc. Studying DNA microarrays for gene-expression analysis can help researchers and 
biologists understand the genomic composition of the biological sample better and discover 
disease causing agents. Genes are involved in the genetic pathway of the disease. Such 
subsets of genes can correspond to gene signatures that provide substantial information about 
the specific biological processes. To obtain these genes, expertise in the field of biology and 
statistics is vital, as well as advanced bioinformatics tools that facilitate such data analysis 
and research, as shown in figure 1. Mining such information from DNA microarrays requires 
an extensive analytical approach. 
 
 
Figure 1: Biomarker discovery in a cross-disciplinary domain 
 
Genomics involves the study of the genome of an organism. The gene intensity level 
measured is called gene expression. Patterns of the gene expressed in a cell reflect the 
characteristics of the state of the cell. The genes involved in these patterns can be identified 
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by adopting various methods available. Some of the techniques are cluster analysis such as 
hierarchical clustering and partition clustering, and machine learning approaches such as 
support vector machines. 
 
The analysis of genomic data therefore can be done in various ways. Extracting meaningful 
biological information with the aid of microarray technology in order to uncover the hidden 
rationale for disease development and progression opens doors to a whole new research area 
called as Biomarker Discovery. Effective and corroborated procedures in gene-expression 
analysis in the biomarker discovery process can be extremely beneficial for disease diagnosis 
and drug discovery and development. These procedures provide powerful information that 
can accelerate the identification of causative genes of various diseases.   
 
Since proteins are also very important in the body’s functions, proteomics study is also 
instrumental in the discovery of biomarkers to indicate a specific disease. Methods that are 
involved in proteomics include 2D-PAGE, MALDI, LC-MS/MS, protein arrays, tissue arrays 
etc (R Fisler, 2005). Proteomics is essentially the large scale study of proteins, mainly their 
structure and function (Wilkipedia, 2001) in a global manner. It is often seen as the following 
step to genomics and is also quite more complicated compared to it. In 2004 a research study 
was conducted that used serum biomarkers for early detection of diseases. In this study (J 
Donald, 2004) a new class of biomarkers was obtained from mass spectrometry analysis and 
did show improved results in early disease detection. Comparative 2d-gel technology 
combined with mass-spectrometry was used by a cohort of scientists (M Carpenter, 2004) to 
discover unique proteins and pathways for biological systems. 2-D gel proteomics potentially 
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presents thousands of proteins which cover a dynamic range of expressions. This group 
devised data processing methods obtain interesting information. There are various online 
protein databanks that provide extensive information on the proteins and help in validating 
results. Some of them are UniProt (Uniprot, 2006), PIR (PIR, 2005), Swiss-Prot (SwissProt, 
2006) and PDB (PDB, 2003). 
 
According to the Food and Drug Administration (FDA), a biomarker is a characteristic that is 
objectively measured and evaluated as an indicator of normal biologic or pathogenic 
processes or pharmaceutical responses to a therapeutic intervention. The detection of this 
substance can indicate a state of disease. There are many ways in which biomarkers are 
useful in the medical domain of science: 
 
 Biomarkers are used for drug discovery research, which involve the exploration of 
appropriate chemicals that target the disease biomarker.  
 Biomarkers are used in clinical trials, as they provide knowledge about the genes 
involved in the pathway of the disease. 
 Biomarkers help in the determination of the tumor type, prediction of survival and 
prediction of response to treatment. 
 Biomarkers aid in the early diagnosis and prognosis of a disease.  
 
The main issue related to discovery of significant genes for a particular disease is the large 
amount of data involved. A microarray chip contains thousands of probe sets with their 
expression values and their detection calls. The major hurdle is finding the set of genes 
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primarily responsible for the disease. For this purpose the list of probe sets needs to be 
brought down to a smaller and more manageable list. 
 
To reduce the number of genes, meaningful analysis is required. The relevant genes are 
widely distributed and the manual study of each and every gene becomes an infeasible task. 
An enhanced automated process to is needed to discard irrelevant genes and preserve the 
important and interesting ones from the initial set of thousands of genes. Simultaneous with 
the exponential growth of available data, the number of available analysis and visualization 
tools has increased dramatically as we have many annotation databases (herein after referred 
to as bioinformatics services). These bioinformatics services assist in condensing the initial 
large set of genes to a list of significant ones. To carry out in-silico experiments researchers 
need a platform where they can build their workflow processes. Building in-silico 
experiments, is a cumbersome and error prone process as researchers need to resolve the 
heterogeneity at the semantic and syntactic level, that is involved in bioinformatics services. 
In-silico refers to the use of computer simulation. SIBIOS, a System for Integration of 
BIOinformatics Services is developed for biological researchers. The aim of this research 
was to develop a workflow-based integration system for microarray research, based on 
SIBIOS. Biomarker discovery used in the environment of workflows is ideally suited for 
automated workflows since there are thousands of identical repetitive steps for each cancer or 
disease studied.  
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1.2. Introduction to SIBIOS 
 
SIBIOS (B. Miled, 2004) is a workflow-based system built with the aim to provide 
researchers with an environment conducive for biological research. It involves access and 
execution of various online bioinformatics tools and biological databases that can be 
combined in an intelligent manner for performing complex queries. It is supported by an 
ontology that is the description of each individual service which is a part of SIBIOS. This 
feature is used as a knowledge base to resolve heterogeneity and interoperability between 
different bioinformatics tools.  
 
The SIBIOS system integrates online web tools and therefore deals with the heterogeneity 
issues persisting in the field of bioinformatics. The formats of the biological data do not 
match even though they mean the same thing. SIBIOS makes working on biological data 
easier so that researchers do not have to worry about the inherent discrepancies in the formats 
in the data. SIBIOS provides researchers an environment and capabilities that allow them to 
define their in-silico experiments in terms of workflow specification, and to control and 
automate them. A sample example workflow supported by SIBIOS is illustrated in figure 2.  
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Figure 2: Sample workflow in SIBIOS 
 
The workflow shown in figure 2 consists of 4 bioinformatics services. A protein is queried in 
the Swissprot and Enzyme search services. The union of the results is fed into Genbank 
which is recursively executed until a certain condition is attained. Genbank’s outputs are then 
finally queried in PIR for the final results. 
 
The field of biomarker discovery has an increasing interest and involves the use of data 
analysis and access to various biological databases for gene information and pathway 
knowledge. Developing such workflows has been the current focus area in the development 
of SIBIOS. Biomarker discovery is an example of such in-silico experiments which have 
been carried out using this system. 
 
Composition of workflows using the SIBIOS framework can aid in biomarker discovery. 
They involve a series of repetitive steps which can be automated for the cancer under study. 
This platform will make SIBIOS a good tool for researchers to work on as it will provide 
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services that include both life science database search services and http based bioinformatics 
applications. The discovery of biomarkers is therefore highly suited for workflow based 
systems like SIBIOS, since a large number of tasks can be automated once the researcher has 
developed his/her design of the protocol.  
 
Biologists can now use SIBIOS to execute their experiments using its new capabilities. 
 
1.3. Research Challenges 
 
Microarray technology is a recent advancement in the field of bioinformatics. With the 
advent of the genome project, there has been a tremendous advancement in the knowledge of 
human genomic sequences as well as other organisms and the genes corresponding to them.  
A number of techniques have been developed for acquiring gene-expression patterns on 
microarray chips. Many experiments are devised to study these gene patterns for their 
cellular responses, biological processes and molecular functions. The simplest way to 
examine these microarray datasets is to find up-regulated and down-regulated genes in an 
altered state compared to the normal state. 
 
The field of Biomarker Discovery is new and several approaches to identify biomarkers are 
being proposed and tested. Biomarker Discovery can be viewed as a three phase process as 
shown in figure 3, i.e. The first phase being data preparation which involves various pre-
processing techniques. The second phase involves the application of various data mining and 
statistical tools that shorten the input gene list to a small list consisting of manageable and 
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significant items. The third phase is the exploratory phase where biomarkers are validated 
using clinical tests, and wet lab experiments. Phase I is a fairly stable phase. Phase II is less 
stable and various approaches have been proposed to carry out this phase. Different studies 
undertaken on the same dataset may lead to a different potential biomarker.  
 
 
Figure 3: Different approaches adopted by different researchers 
 
To provide researchers with a workflow framework one needs to study a number of 
approaches, analyze them in detail and then determine a protocol that highlights the number 
of steps and the tools that can be used at each of the steps. The main challenge that 
undermines adapting a workflow-based system such as SIBIOS is the lack of standard 
protocol models that can be used as templates for proposing the basic building blocks for 
biomarker discovery. Therefore the integral part of the solution is to devise models for 
biomarker discovery experiments. As a proof of this concept, a specific type of cancer is 
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studied here and used to design a protocol that leads to construction of a sample model to be 
added to SIBIOS and at the same time aim for the discovery of biomarkers.  
 
Understanding the features of the dataset and the experiment’s goal is essential to apply the 
experimental procedures correctly. The design and implementation of a successful software 
program for correct protocols is a challenge for efficient analysis and data collection. These 
protocols involve a number of statistical methods and tests. Inappropriate statistics can be 
misleading hence; statistical results should be interpreted in the context of the experimental 
study and its purpose. Otherwise issues may arise related to the microarray results as they 
depend on the validity of the statistics applied. Certain considerations before applying 
statistical tests generally involve assumptions on the normality of distribution of the data. 
Such factors become the basis of applying parametric or non-parametric tests.  
 
Various approaches exist to carry out biomarker discovery. The main goal is to identify a list 
of significant genes that have relation to the disease under study. The approaches can be 
classified into two techniques: 
 
 Usage of data analysis first and then using annotations to validate biomarkers. 
 Utilize annotations first and then use the analytical approaches to obtain a set of 
potential biomarkers. 
 
The second challenge is that SIBIOS has been designed as a generic open-ended workflow 
integration system; and as such it focuses on meeting several requirements for building in-
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silico experiments. Adapting SIBIOS to biomarker discovery creates new research 
challenges, such as the ability to manipulate analytical tools, maintain sessions while using 
http-based bioinformatics services, facilitate the use of stand-alone tools, etc..  
 
The difficulty in establishing a protocol constitutes a challenge to adopt SIBIOS as a 
platform for biomarker discovery. The issues involved mainly are: 
 Understanding the microarray dataset. 
 Tackling the complexity of the analytical tools. 
 Pre-processing factors affecting the results (i.e. whether the data is normalized or not, 
or if it has been transformed appropriately) 
The results of biomarker discovery depend on such factors.  
 
1.4. Contributions 
 
This thesis addresses the main challenges and provides the following contributions to this 
solution of biomarker discovery using SIBIOS. 
1. Development of sample models of the workflow that can be used as a template for a 
biomarker discovery pipeline. 
2. Adaptation of SIBIOS to allow the building of workflows supporting such workflows. 
3. Identification of new interesting biomarkers targeting BCR-ABL, a subtype of Acute 
Lymphoblastic Leukemia.  
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To develop sample protocols, a case-study was identified to explore and validate the 
approach used. A microarray dataset of 132 samples from the St Jude’s organization (M E 
Ross, 2003) was selected as a target dataset for the purpose of this research.  
 
The validation of the new proposed protocol resulted in the identification of potential 
biomarkers as the direct or indirect “disease causative agents.” 
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2. BACKGROUND 
 
2.1. Related Research 
2.1.1. Workflow environment for in-silico experiments  
 
A considerable amount of work has been done in the field of bioinformatics particularly on 
microarrays. According to the Nucleic Acid Research Database issue published in January 
2005 (Galperin, 2005), more than 850 biological databases exist, with around 548 in 2004 
and 368 in 2003. Consistent with the increasing growth of available data has been the growth 
and development of bioinformatics analysis and visualization tools. In spite of the abundance 
of accessible online bioinformatics tools, designing and performing in-silico experiments has 
been an inefficient and laborious task. The main reasons have been: 
 The highly diverse nature of the data stored in biological databases. 
 The inherent heterogeneity within the data. 
 The immense querying capabilities provided by other resources.  
 The incompatibility of data between the different bioinformatics services. 
Because of these factors, using bioinformatics services has been quite difficult as well as 
time consuming. Typically for the identification of biomarkers in the blood of a diseased 
patient, a researcher utilizes the gene expression data available from various public online 
databases. The potential markers most likely lie in the cancerous tissues of the body. Such 
microarray datasets are usually made available as raw datasets and are need to be normalized 
or transformed, after which statistical tests are performed to select differentially expressed 
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genes. These differential genes are then further annotated in public databases for information 
such as cellular function, biological process and pathways the gene is involved in.  
 
Apart from gene expression data, study of proteins also gives useful information. Proteomic 
data provides the protein expression levels in the blood of the human body. Proteins in the 
proteomic datasets generated by methods such as LC/IMS mass spectrometry are identified 
by searching several sequence databases which involve search algorithms. The results 
obtained then need to be validated using biological annotations. To find an emerging 
significant protein pattern in the patient’s blood sample, the data has to be pre-processed for 
normalization, transformation and then analyzed using heuristic methods. Obviously 
biological researchers need to have a workflow based system which would save a substantial 
amount of time for them. Therefore the need arises for not only database integration but also 
the incorporation of analytical tools. Such data integration systems substantially reduce the 
time involved to perform in-silico experiments.  
 
Several systems have been proposed which provide a framework for carrying out workflow 
based biological experiments. Many ongoing projects that have been developed deal with 
bioinformatics service integration. They include Bio-MOBY (M Wilkinson, 2005) , 
MyGRID (MyGRID, 2004) , Taverna (T. Oinn, 2004), Transparent Access to Multiple 
Bioinformatics Information Sources (TAMBIS) (R Stevens, 2000) and Kepler (B Ludascher, 
2004). Bio-Moby system is classified into two divisions i.e. Moby-s and s-Moby. MyGRID 
is a loosely coupled suite of middleware components to support in-silico experiments in 
biology. TAMBIS also is an application that allows query bioinformatics resources. Kepler is 
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a particular scientific workflow system that involves analytical steps of database access and 
querying, data analysis and mining, and many steps including computationally intensive jobs. 
These projects employ different techniques for achieving biological web-services inter-
operability. The main aim is to develop a robust integration system to incorporate 
bioinformatics services for biomarker identification in in-silico experiments with microarray 
data. 
 
SIBIOS is a similar system developed to facilitate biological workflows and also has certain 
distinctive capabilities. SIBIOS successfully allows integration of bioinformatics tools 
including data sources and analytical applications and also assists researchers to run in-silico 
experiments according to their workflow specifications. SIBIOS has the key features 
necessary for the platform i.e. to control the execution and also to automate workflows in it.  
 
All workflow-based systems have the capacity to provide workflows for general experiments. 
SIBIOS however has the additional key features necessary for the platform to assist in 
building and controlling workflows. The system supports general purpose services like PDB, 
SwissProt, NCBI Gene, BLAST, FingerPrintScan and many more. These services meet 
general requirements of in-silico experiments and are not targeted towards the automation of 
microarray analyses like biomarker discovery.  
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2.1.2. Microarray analysis for Biomarker Discovery 
 
Microarrays have emerged as a great technology for unfolding the mysteries and reasons for 
abnormal gene expression. It is the most promising clinical application of modern genomics. 
It opens a prospective for more reliable and efficient diagnosis of tumors, prediction of 
response to treatments, and risk group determination. 
 
A typical oligonucleotide microarray would look like a 2 x 2 array (figure 4) consisting of 
spots in various shades of red, green, and yellow. The color of each spot corresponds to the 
intensity level of a gene expressed in a particular sample. These gene expression values are 
measured with great precision, and they become the basis of the microarray gene expression 
analysis. There are various instruments used to measure the expression level of each spot 
from the image of a microarray chip. These instruments are based on image processing 
concepts. 
 
         Figure 4: Microarray chip image 
 
An instrument available commercially for gathering microarray data is Agilent 2100 
Bioanalyzer (Agilent, 2000) for assessing the RNA integrity. Arrays can be scanned using a 
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laser confocal scanner and expression values can be calculated using certain software like 
Affymetrix Microarray software (MAS) (Hardware, 2004). But sometimes even 
measurement with immense precision can contain certain inherent errors which can give 
incorrect results (C S Brown, 2001).  
 
While working on microarrays, it is necessary to identify the goal of the study. The 
hypothesis becomes the basis on which statistical analysis on the experimental research is 
performed. The analysis of the data depends on the following factors: 
1. Type of dataset (cDNA, oligonucleotide microarray etc.) 
2. Normalized or raw data  
3. Statistics used based on number of independent/dependent variables 
4. Purpose of study i.e. what results are need 
Microarray analysis is based on the study of gene expression levels. For the purpose of 
discovery of biomarkers in the blood of diseased samples, gene expression data are utilized 
and processed. The objective of the experimental design here is to trouble shoot a sample 
protocol and transform it into a robust process. To develop a biomarker pipeline, a series of 
steps need to be identified. The main steps include: 
1) Data Pre-processing 
2) Data Analysis 
a. Analysis-first Annotation-second Model 
b. Annotation-first Analysis-second Model 
3) Biological Analysis 
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2.1.2.1. Data Pre-processing 
Pre-processing is the step that enhances the data quality and improves the identification of 
meaningful characteristics in the dataset. Pre-processing also prepares the data for the 
application of analysis methods. A popular pre-processing technique is the transformation of 
the initial gene expression to the logarithm of the raw values. Normalization is another 
procedure applied to account for the systemic differences in the datasets. It is generally 
applied to modify the values in order to reduce the noise signals in microarray experiments 
using different dyes, i.e. Cy3 and Cy5. Data transformations also depend on the type of 
microarray data under study. Certain logarithmic transformations are equally applicable to 
cDNA and Affymetrix datasets, while other methods like background correction and probe-
level pre-processing are specific to a given technology. Some of the top preprocessing 
methods that are applicable in the context of microarray experiments are described below 
(Draghichi, 2003; Speed, 2003). 
 
1) Log Transform 
Logarithmic transformations have been used widely for a long time. They provide 
transformed data that are easily interpreted and are more biologically meaningful. It is 
effortless to transform gene expression values in order to eliminate the misleading 
disproportions between two relative changes in two different pairs of values. For example,  
Log transformation of base 10 will transform these values into: 
log10 (100) = 2, log10 (1000) = 3, and log10 (10000) = 4 
This reflects the case that these genes are affected in the same way, only that they are 
transformed in different proportions. That is, 2 – 3 = -1 and 4 – 3 = 1. 
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These genes are affected by the same magnitude but in different directions. Log 
transformations also contribute in partially reducing the variance and the mean intensity in 
the data. Another advantage of the log transformation is that the data becomes symmetrical 
and almost normally distributed.  
 
Finally, if log of the base 2 is taken then it helps in the data analysis and interpretation. For 
example, selecting genes with 4-fold variation can be done by cutting a ratio histogram at the 
value log2 (ratio) =2.  
 
2) Array Normalization 
The main aim of using microarrays extensively is to make random comparisons between 
gene expression levels in various conditions and tissues possible. For that purpose it is 
essential for the data to be normalized so that the processed data are independent of the 
specific experiment and technology used. Currently, no standard way for normalizing the 
microarray data in a universal manner has been achieved. It is still under question whether 
the data obtained from different technologies like oligonucleotide and cDNA arrays can be 
compared directly. Yuen et al (T Yuen, 2002) reported a fairly good correlation between the 
expression data measured with GeneChip and the cDNA chip, while Kuo et al (W Kuo, 
2002) found no correlation. The difficulty may be due to the overall difference in the 
intensities measured. The goal here is to normalize the arrays in such a way that the values 
corresponding to the individual genes can be compared directly from one array to another. 
Some of the methods to achieve that are: 
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 Divide the intensities by the mean before the log transformation. This method is 
equivalent to the correction using arithmetic mean. 
 Subtract the mean from the intensities after the log transformation. It is similar to 
the correction using the geometric mean. 
 
3) Normalization issues specific to Affymetrix data 
The Affymetrix technology and the data processing techniques are provided by the company 
itself. As a result most laboratories pre-process Affymetrix data in the same manner.  
Some of the ways in which Affymetrix data are preprocessed are: 
 Background correction 
Cell intensities are corrected for background using some weighted average of the 
backgrounds in the neighboring zones. A Perfect Match (PM) probe is a 25-mer 
oligonucleotide designed to be complementary to a reference sequence. The probe 
sequence is complementary to the sequence to be hybridized. A Mismatch (MM) probe is 
a 25-mer oligonucleotide designed to be complementary to a reference sequence except 
for a single, homomeric (nucleotide mismatch that contains the complementary base to 
the original) base change at the 13
th
 position (Affymetrix, 2002). An Ideal Mismatch (IM) 
value is calculated and subtracted from the PM intensity. If the MM is lower than the PM, 
the IM is taken to be as the difference (PM-MM). The adjusted PM values are then log 
transformed and the robust mean of the log transformed values are then calculated.  
 Signal calculation 
The signal value is calculated as the exponential of this robust mean and scaled using a 
trimmed mean. 
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 Detection call 
The detection call of a gene signifies if the gene is present in well above the minimum 
detectable level (P), absent (A), meaning that the gene expression is below the minimum 
level and Marginal (M) signifying that the gene is present in the near to minimum levels. 
A discrimination score (R) is calculated for these probe pairs and based on the limit (τ) 
used, the probe pairs are discarded. By default, τ = 0.015. Increasing τ reduces the 
number of false positives but also reduces the true detected calls.  
 
      2.1.2.2. Data Analysis 
In many cases, the aim of microarray experiments is to compare gene expression levels in 
two different samples. They are generally experimental samples comparing normal data with 
diseased data. In such experiments biomarkers are the potential genes that are differentially 
expressed in the two samples compared.    
 
There has been a considerable amount of work done in the field of bioinformatics for 
significant gene selection. Numerous computational methods have been implemented such as 
statistical classifiers, significant pattern detection, and bioinformatics service integration 
systems. In order to formulate a protocol for a microarray experiment, the computational 
analysis of gene expression as well as biological annotations of the significant gene set needs 
to be conducted in an organized manner. There are two approaches that can be used in order 
to carry out the data analysis of the genes. They are namely Analysis First-Annotation 
Second Model and Annotation First-Analysis Second Model: 
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a) Analysis First-Annotation Second Model 
In order to obtain a list of differentially expressed genes, many computations are required on 
the gene expression data set. There are many methods that have been developed which can be 
applied to microarray data. The procedures can be classified into 3 main categories: 
 
 Machine Learning Methods 
Some of the types of machine learning methods are decision trees, support vector 
machines, and principal component analysis. 
1) Decision Trees 
Decision trees are based on a rule induction algorithm. This method is generally used 
where systematic selection of a small number of features is used for a decision 
making process. It increases the comprehensibility of the knowledge patterns. A 
decision tree is a NP-complete problem. Its construction is based on the fact that the 
root node of the tree is determined first and then the root nodes of its sub-trees. Every 
feature can be used to partition the training data. If the partitions contain a pure class 
of training instances, then this feature is most discriminatory. A decision tree based 
approach was applied in a research study (D Singh, 2002) to study the expression 
levels in a prostate cancer dataset. It is applied for the main purpose of classification 
by grouping genes with similar patterns. 
 
2) Support Vector Machines (SVM) 
Support vector machine is a supervised learning algorithm that determines a small 
number of critical boundary instances from each class and then construct a linear 
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discriminant function that separates them as widely as possible (H Witten, 1999). It 
addresses the problem of learning to distinguish between positive and negative 
members of a given class of n-dimensional vectors. The SVM algorithm operates by 
mapping a training dataset into a high-dimensional feature space and attempting to 
locate in that space a plane that separates the positive from the negative as shown in 
figure 5.  
 
 
Figure 5: Mapping of input to feature space by "kernal" function (A Zien, 2000)  
 
Using this information, the SVM can then predict the class of an unknown sample by 
mapping it into the feature space. Support vector machines have been used by Koike 
et al in a study where the prediction of protein-protein interaction sites is done using 
sequences (A Koike, 2004). In this study the identification of protein-protein 
interaction sites was important for mutant design and prediction of protein-protein 
networks. The interaction sites were predicted using SVM and profiles of spatially / 
sequentially neighboring residues. Another research group used the theory of SVM to 
classify genes by using gene expression data from microarrays. They used SVMs to 
predict functional roles for uncharacterized yeast ORFs based on their expression data 
(M Brown, 2000). 
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3) Principal Component Analysis (PCA) 
A single microarray analysis experiment can generate measurements for thousands of 
genes. Principal component analysis allows defining a core set of independent 
features for the experiment state and allows them to be compared directly.  
 
It is a very good statistical technique to identify the significant components in a multi 
dimensional dataset to identify the differences in the observations. It provides a good 
visualization outline of the data. When PCA is applied to gene expression data, we 
can get a summary of the way in which gene responses vary under different 
conditions. There are many tools like Spotfire (SpotFire, 1996) and Matlab 
(MATLAB, 1994) that can be used to apply PCA. Figure 6 shows the illustration of a 
plot of PCA where clusters are made with each describing a particular feature of a 
data set. 
 
Figure 6: View of dataset using PCA in MATLAB 
 
A research study conducted in 2006 (S Raychaudhari, 2000) is an example of 
microarray study using PCA. 
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 Data mining methods 
Data mining refers to the process of extracting useful and meaningful information 
from a large dataset or database. Examples of data mining techniques used include 
association rules and emerging patterns.  
1) Association Rules 
Association rules are devised for larger databases with moderate features. But 
however they have been adopted in the context of microarrays to take into account 
microarray analysis. Association rules are essentially of the form LHS → 
Consequent. The LHS is a set of items. It is called the anticipant of the rule and the 
right hand part consists of the consequent part of the rule. Every rule is associated 
with a support and confidence. The number of rows in a dataset that match an 
association rule is called the support of that rule and the probability of that rule being 
true is called the confidence of the rule. Certain mining algorithms can be applied in 
the context of microarray analysis in order to obtain association rules. This is a 
fascinating approach as many biologically interesting rules can be obtained. As 
compared to random data results, these rules are reliable and are not by chance. In the 
application of bioinformatics Creighton and Hanash used data mining to find such 
association rules from expression profile of yeast (C Creighton, 2003). They obtained 
a number of rules that made sense biologically, and many others suggested new 
hypotheses that could be investigated further.  
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2) Emerging Patterns  
Emerging patterns are basically related to two classes. The patterns signify the 
discriminating features between the two datasets. It is a challenge to obtain a 
manageable set of emerging patterns that are easily understandable to the researcher. 
Therefore the issue of efficient discovery arises. In order to implement this 
methodology, there are different algorithms that can be applied. E.g. border based 
algorithms were applied to discover the most specific and most general emerging 
patterns from large datasets (J Li, 2001).  
 
b) Annotations First-Analysis Second Model. 
This is a novel approach that has been adopted by recent research groups. The idea is to use 
gene annotations before applying statistical computations in a given microarray dataset. This 
procedure takes into account the molecular heterogeneity of the different characteristic 
expression patterns in different patients. In addition to the expression data that is utilized to 
find significant genes, such approaches utilize the functional annotations from the Gene 
Ontology (GO, 1999) database. A research group from Germany developed a novel 
algorithm called Structured Analysis of Microarrays (StAM) (C Lottaz, 2005). They have 
taken advantage of the functional annotations from the Gene Ontology database to build 
biologically focused classifiers. They classifiers are then used to discover potential molecular 
disease sub entities and associate them to biological processes without compromising overall 
prediction accuracy.  
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2.1.2.3. Biological Analysis 
This is the last step to biologically validate the subset of genes obtained by either of the two 
approaches. For this purpose, their annotations are studied in detail. Various online biological 
databases are used such as OMIM (OMIM, 1994), and DAVID (DAVID, 2006). The 
biological meaning is utilized to relate the gene to the disease under study. 
 
Various groups have been working on biomarkers for various different reasons. Some of 
them are for disease classification purposes, some for drug discovery, and a few for the 
identification of genes responsible for the disease in clinical applications. In 2004 a group of 
researchers from Germany were investigating the possible future application of gene 
expression profiling for the diagnosis of leukemia (A Kohlmann, 2004). They were working 
on demonstrating that gene signatures defined for childhood Acute Lymphoblastic Leukemia 
(ALL) were also capable of stratifying distinct subtypes in a cohort of adult ALL patients. 
This was a promising finding as global gene signatures were being identified by microarray 
expression analysis. Microarray technology has been used over the years for various 
purposes. Another group of collaborators devised an approach to predict new classes of 
cancer without any prior knowledge of it (T.R. Golub, 1999). The results demonstrated the 
feasibility of cancer classification by gene expression monitoring and the researchers 
developed a strategy to discover and predict cancer classes without any previous biological 
knowledge. Another research group has studied the cell lines of leukemia and identified the 
chromosomal abnormalities associated with them (B M Fine, 2004). When these cell lines 
were studied together with the clinical samples, it was found that each chromosomal 
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abnormality was associated with a characteristic gene expression signature specific to the cell 
line and the clinical sample.  
 
Even though there are numerous methods to carry out research in biomarker discovery, there 
are no set standards adopted universally. These different studies on the same microarray 
dataset lead to different results. In a study conducted in 2001, a technique was utilized by the 
researchers to compare the results of different statistical approaches (M K Kerr, 2001). This 
study signifies the absence of set standards because of the lack of agreement with respect to 
following a universal procedure in the area of biomarker discovery.  
 
2.2. Some results in Biomarker Discoveries 
 
There has been active research for the detection of cancer biomarkers. In the recent years 
biomarker discovery has been a major focus of cancer research. Many investments have been 
made for early detection of cancer. Back in 1965, Dr Joseph Gold found out a test for 
recognizing a common cancer (S K Chatterjee, 2005). A substance from the patient’s blood 
having colon cancer was found and this substance is normally found in fetal tissues. He 
named it carcinoembryonic antigen (CEA). In the 1980’s more biomarkers were found such 
as CA 19-9 for colorectal and pancreatic cancer, CA 15-3 for breast cancer and CA-125 for 
ovarian cancer. They have been proven to be early markers for reliable indicators of early 
disease as they are present in basal levels in normal people and higher concentrations in 
cancerous individuals. But these markers were not specific for a particular cancer. Lung 
cancer also often had elevated levels of CEA and CA-125 in women.  
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Till now, prostate-specific antigen (PSA) has been the best-known cancer biomarker for early 
detection of prostate cancer. It has been used for screening, diagnostic purposes as well as 
monitoring disease recurrence. PSA is the only biomarker to be approved by FDA. Some of 
the biomarkers that have been identified are given in Table 1. (S K Chatterjee, 2005) 
 
Table 1: Cancer biomarkers and their use. 
Biomarkers Cancer Use 
PSA Prostate  Screening, diagnostic, predict recurrence 
CEA Colorectal, lung, breast, liver, 
pancreatic, thyroid, liver 
Determine recurrence, monitor treatment, 
efficacy 
CA 125 Ovarian Diagnostic, monitor treatment, predict recurrence. 
BTA Bladder Diagnosis, predict recurrence 
Calcitonin Thyroid Diagnosis, monitor treatment and predict 
recurrence. 
Vimentin Kidney Prognosis 
Myc and A1B1 Hepatocellular carcinoma Prognosis 
SELDI pattern Ovarian cancer Diagnosis, prognosis stage 
MMP Prostate, breast Prognosis 
ICTP Ovarian Prognosis, stage. 
 
All these biomarkers have not been approved by FDA. Some reasons for the lack of FDA 
approval are that most of these biomarkers are of limited clinical use. Many have lacked 
epidemiological validity or statistical power so they are deficient in universal application. 
Approval of PSA has motivated researchers to identify suitable markers for other cancers and 
improve the present predictive capability of cancers. 
 
       2.3. Biology of Leukemia  
   
The evolution of a normal cell into cancer involves disruption and deregulation of a number 
of basic cellular processes. Multi cellular organisms, in their evolution have developed 
redundant controls through which the homeostasis between different cell types is maintained. 
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One of the safeguards that prevent excess cell accumulation is a cell-intrinsic program that 
can induce cell death through apoptosis. The growing understanding that transforming 
mutations can activate this intrinsic apoptotic response has emphasized the importance of this 
process in preventing cancer cell development. Apoptosis control mechanisms appear to be 
impaired in virtually all tumors, suggesting that a required step in carcinogenesis is to 
disengage the apoptotic machinery and hence it will be beneficial to understand the 
mechanisms by which normal cells become malignant but also to prevent and treat cancer in 
humans. 
 
The term leukemia refers to cancer of the white blood cells. The word "leukemia" means 
"white blood" in Greek.  Under normal circumstances, the blood-forming, or hematopoietic, 
cells of the bone marrow make leukocytes to defend the body against infectious organisms 
such as viruses and bacteria. But if some leukocytes are damaged and remain in an immature 
form, they become poor infection fighters that multiply excessively and do not die off as they 
should (MamasHealth, 2000).   
 
 
Figure 7: Leukemic cells under a microscope 
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The leukemic cells accumulate and lessen the production of oxygen-carrying red blood cells 
(erythrocytes), blood-clotting cells (platelets), and normal leukocytes (figure 7). If untreated, 
the surplus leukemic cells overwhelm the bone marrow, enter the bloodstream, and 
eventually invade other parts of the body, such as the lymph nodes, spleen, liver, and central 
nervous system (brain, spinal cord). In this way, the behavior of leukemia is different than 
that of other cancers, which usually begin in major organs and ultimately spread to the bone 
marrow.  
 
As leukemia progresses, the cancer interferes with the body's production of other types of 
blood cells, including red blood cells and platelets. This results in anemia (low numbers of 
red cells) and bleeding problems, in addition to the increased risk of infection caused by 
white cell abnormalities. As a group, leukemia accounts for about 25% of all childhood 
cancers and affect about 2,200 American young people each year. With the advance in 
medical science and ongoing research the chances for a cure are very good with leukemia. 
With treatment, most children with leukemia are free of the disease without it coming back. 
 
Normal human body has controlled levels of white blood cells in the blood. ALL is a quickly 
progressing disease in which a lot of immature lymphoblasts are found in the bone marrow 
and blood. Bone marrow normally produces stem cells (which are immature blood cells). 
These later develop into mature blood cells (figure 8). Mature blood cells are of three types: 
a) Red blood corpuscles (RBC) 
b) White blood corpuscles (WBC) 
c) Platelets 
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During the progression of leukemia, another kind of white blood cells called as lymphocytes 
are produced in increased amounts. In ALL lymphocytes do not fight infection well. 
Lymphocytes increase in the blood and bone marrow thus making less space for healthy 
WBC, RBC and platelets. These inefficient lymphocytes occur in three kinds in the blood 
which are: 
a) B – Lymphocytes 
b) T – Lymphocytes 
c) Natural killer cells ( they attack viruses ) 
 
Figure 8: Development stages of Lymphocytes 
Pediatric ALL is a heterogeneous disease consisting of various subtypes. One of our 
objectives is to identify significant relevant genes specific to the various subtypes of ALL. 
The purpose is to appropriately recognize the subtype as they all vary markedly in their 
course of treatment. Given the right treatment, recovery rates are good and chances of relapse 
of the disease are less. The 6 major subtypes of leukemia are: 
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1. BCR-ABL t(9;22) 
2. E2A-PBX1 t(1;19) 
3. TEL-AML1 t(12;21) 
4. Rearrangements in MLL gene on chromosome 11 
5. Hyperdiploid karyotype ( >50 chromosomes) 
6. T lineage leukemia (T-ALL) 
The same protocol developed is applied for each of the six subtypes. We will analyze BCR-
ABL in the next section to identify significant genes corresponding to it.  
 
Occurrence of BCR-ABL gene 
 BCR (Breakpoint cluster region gene) encodes for BCR protein with locus at 22q11. 
It functions as a GTPase activating protein. 
 ABL (Abelson’s murine leukemia viral oncogene) gene has a locus at 9q34 and 
functions as a non receptor tyrosine kinase. 
Leukemic (BCR-ABL subtype) cells have an abnormal feature called the Philadelphia 
chromosome. The Philadelphia chromosome results from a mutation called a translocation 
(two chromosomes break, then parts from each chromosome switch places). In BCR-ABL, 
the translocation occurs between chromosomes 9 and 22 (human DNA is packaged in 23 
pairs of chromosomes) and produces a new, abnormal gene called BCR-ABL. This abnormal 
gene produces BCR-ABL tyrosine kinase, an abnormal protein that causes the excess WBCs. 
BCR-ABL is associated with a more heterogeneous pattern of gene expression and poor 
clinical outcome. 
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The Philadelphia chromosome is an acquired mutation i.e., a person is not born with it and 
does not pass it on to his/her children. Exactly why the Philadelphia chromosome forms is 
unknown in most cases, although exposure to ionizing radiations has been shown to be one of 
the causes for such abnormality. 
 
Based on the biological processes that BCR-ABL is involved in, the results are analyzed. The 
purpose is to study how the set of genes obtained as significant, are involved in the abnormal 
process that is created due to the translocation of the BCR and ABL genes. 
 
In the following sections we will identify the main statistical and biological approaches that 
will be used in the identification of the potential biomarkers. Initially, the concentration has 
been on the subtype BCR-ABL, for its significant genes. The same protocol can then be 
applied for the rest of the 5 Leukemia subtypes. 
 
Integral part of this research is to use the existing SIBIOS system for conducting biomarker 
experiments. The next section describes the SIBIOS workflow integration system. 
 
2.4. Description of SIBIOS 
 
SIBIOS (B. Miled, 2004) is a system for executing biological workflows in the 
bioinformatics domain. By making rich set of biological databases and annotation tools 
available, researchers can transparently utilize the output of one bioinformatics service as an 
input for another bioinformatics service. Several challenges have been encountered during 
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the design of SIBIOS to enable the seamless integration of bioinformatics services. These 
challenges are mainly twofold.  
 The heterogeneities that characterize bioinformatics services at the syntactic and 
semantic level. 
 The nature of biological workflows that are characterized by: 
o An experimental phase where different services and their composition within 
a workflow undergo a discovery phase. 
o A production phase where automation of the workflow execution is necessary. 
 
2.4.1. SIBIOS Architecture 
 
SIBIOS is designed as a multi-tier client server architecture. The client module builds the 
workflows as specified by the user with the help of service composition. This workflow 
specification is then sent by the client to the workflow enactment module. SIBIOS’s 
knowledge base contains the semantic as well as ground level description of service. The 
description of each service is in the form of five properties available as a part of SIBIOS’s 
ontology. These properties are used to describe a set of features by which a service can be 
searched in SIBIOS. These properties for a particular bioinformatics service relates to the 
input accepted (has_input), output obtained (has_output), task performed (perform_task), 
algorithm used (is_function_of) and the resources accessed by the tool which are mainly 
databases (use_resource). Not all properties are utilized by a bioinformatics service. The low 
level description of the bioinformatics service is also given in the form of an XML schema 
also called as service schema. It is accessed by the server to ensure service execution during 
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the enactment. The knowledge base admin/Service Publishing module is used for the 
maintenance of the knowledge base.  
 
 
Figure 9: SIBIOS architecture 
 
The overall architecture of the SIBIOS system is shown in figure 9. The user interacts with 
SIBIOS through the GUI module to construct the workflows according to his/her 
requirements. Workflow building is aided by the service selection module or the automated 
service composition module. The automated service composition allows the user to submit a 
high level description of the workflow, and later generate a list of potential workflows that 
meet the user’s requirements. The user can then select the most appropriate one for 
execution. This module is still under development. The workflow enactment module interacts 
with many other modules to achieve the specifications of the scientific workflow. Sometimes 
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there maybe a failure in any of the components of SIBIOS and may halt the execution of the 
workflow. The fault tolerance framework addresses these failures in a manner to fulfill the 
objective of the system even on failure of these components.  
 
2.4.2. Workflow Design 
 
2.4.2.1. Service Selection 
The user constructs the workflow he/she wants to execute using the graphical user interface 
module of SIBIOS. It is done by sequentially adding and linking the services that one desires 
to execute. SIBIOS presents two approaches to the user for workflow construction. One 
approach is through the service discovery dialog box (B. Miled, 2004) and the second 
approach is through the service browsing facility. For the former case, SIBIOS provides a 
service browsing facility that supports classification of the services by using properties such 
as has_input, perform_task, etc.. Knowing which task is needed to be performed, the user can 
select the application required to include in the workflow. For the latter case, the user can 
search for the service desired through the service discovery facility by combining more than 
one property and then add it to the workflow (L. L. M Mahoui, J Chen, N Gao, 2005). This 
increases the precision by which the services are discovered as more search elements are 
considered and this option is generally used by more sophisticated users. A service discovery 
process can help the user identify the services that are needed in the workflow based on the 
requirements (e.g. has_input, perform_task, etc.) of the service to be executed. It is an 
intelligent discovery system that utilizes the properties of the services rather than the name of 
the database or the bioinformatics tool. This allows researchers unfamiliar with large amount 
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of available bioinformatics services to select the appropriate application for a workflow. The 
service browsing approach allows the user to progressively drill down through the list of 
available services using either one of the service properties. Figure 10 and 11 shows how 
these two service selection facilities are deployed in SIBIOS. To select the next service to be 
added to the workflow two main cases are considered. Either the user knows the name of the 
next service to be added. Or the user does not have the information, but he is capable of 
describing the service he/she wants to add using some features such as service input.  
 
Figure 10: Service Discovery facility on SIBIOS 
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Figure 11: Service Browsing Facility in SIBIOS 
 
As discussed before each module in the workflow corresponds to a web application that 
provides a particular service. For the execution of the workflow the information needed to 
contact those services successfully are provided in the schemas that reside in the knowledge 
base of the system.  
 
2.4.2.2. Service Composition 
Service composition is the process of SIBIOS that connects the various services into a 
meaningful workflow. Two services can be connected in a workflow only if the input 
parameters of the latter service match the output parameters of the targeted previous service. 
There are various service connectors (join, union, iteration, pause) available in SIBIOS to 
join different services (Z. M. M Mahoui, S Srinivasan, M Dippold, B Yang, N Li, 2006). The 
usage of these operators is illustrated in the sample workflow in figure 2. The red box in the 
workflow is a filter operator used to pass user-specified information to the subsequent 
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service. The green box corresponds to the join operator that combines the results from 
‘SWISSPROT_SEARCH_SERVICE’ (SwissProt, 2006) and 
‘ENZYME_SEARCH_SERVICE’ (Enzyme, 2000) before it is sent to 
‘GENBANK_SEARCH_SERVICE’ (Gene, 2004). The yellow box is used to execute 
repeatedly on a particular service until a certain condition is achieved. And the hollow yellow 
circle over an arrow connecting two services is used to pause the workflow execution for 
user intervention in defining service parameters. A pausable service allows the users to take 
decisions after viewing the results from the previous result in a better way. He/she can define 
service parameters and select inputs for the next service based on the results he/she views 
from the previous service. 
 
2.4.3. Workflow Enactment 
 
Workflow enactment module is a complex engine that interacts with various components in 
the SIBIOS system to achieve the goals of the scientific workflow. The workflow composed 
by the user is defined in an XML file. This description of the workflow is used by the 
workflow enactment module. The XML file is then sent to the server of SIBIOS and is 
validated by a DTD file supplied at the server side. The remote connection with the 
bioinformatics service is done using the service schemas stored in the knowledge base. This 
service schema contains the detailed information of the service to be executed. A sample 
service schema is illustrated in table 2. There are four main parts in the schema that contain 
detailed information of the bioinformatics service. They are SERVICE_APPLICATION, 
URL_STRING, EXTRACTION_RULES and INTERFACE_PARAMETERS.  
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Table 2: Sample XML Schema 
 <?xml version="1.0" encoding="ISO-8859-1" standalone="yes" ?>  
 <TOP> 
 <SERVICE_APPLICATION> 
  <SERVICE_NAME>swisspfam_service</SERVICE_NAME>  
-         <PATH_PAGE> 
             <PAGE_CHARACTER>atv</PAGE_CHARACTER>  
             <EXTRACT_LINK>sh='{title}pfam' t='{/title}' l='for ' r=''</EXTRACT_LINK>  
          </PATH_PAGE> 
 </SERVICE_APPLICATION> 
 <URL_STRING> 
-         <SINGLE_QUERY> 
          <BASIC_URL>http://www.sanger.ac.uk/cgi-bin/Pfam/swisspfamget.pl</BASIC_URL>  
              <METHOD>P</METHOD>  
           <DEFAULT_PARAMETERS />  
           <SWISSPROT_ACCESSION_NUMBER>name=XXXX</SWISSPROT_ACCESSION_NUMBER>  
           <SWISSPROT_ENTRY_NAME>name=XXXX</SWISSPROT_ENTRY_NAME>  
           </SINGLE_QUERY> 
 </URL_STRING> 
 <EXTRACTION_RULES> 
          <DOMAIN_INFORMATION> 
         gh='{tr class=normaltext }' t='--form stuff--}' s='{tr class=normaltext }'  
           <DATA_STORE>sh='{td ' t='{/tr}' l='align center' r='{A HREF'</DATA_STORE>  
           <DOMAIN_NAME>sh='{td ' t='{/tr}' l='{b}' r='{/b}'</DOMAIN_NAME>  
           <DOMAIN_ACCESSION_NO>sh='href=/cgi-bin/pfam' t='}' l='getacc?'            
r='}'</DOMAIN_ACCESSION_NO>  
           <SEQUENCE_START>sh='{td ' t='{/tr} l='{td''{td''{td''}' r='{/td}'</SEQUENCE_START>  
           <SEQUENCE_END>sh='{td ' t='{/tr} l='{td''{td''{td''{td''}' r='{/td}'</SEQUENCE_END>  
           </DOMAIN_INFORMATION> 
 </EXTRACTION_RULES> 
 <INTERFACE_PARAMETERS> 
           <MAN_OR> 
           <PARAMETER> 
           <NAME>SWISSPROT_ACCESSION_NUMBER</NAME>  
           <DESCRIPTION>Swiss-Prot Accession Number</DESCRIPTION>  
           <TYPE> 
           <TEXTFIELD />  
           </TYPE> 
           <DEFAULT_VALUE />  
           </PARAMETER> 
           <PARAMETER> 
           <NAME>SWISSPROT_ENTRY_NAME</NAME>  
           <DESCRIPTION>Swiss-Prot Entry Name</DESCRIPTION>  
           <TYPE> 
           <TEXTFIELD />  
           </TYPE> 
          <DEFAULT_VALUE />  
         </PARAMETER> 
         </MAN_OR> 
  </INTERFACE_PARAMETERS> 
</TOP> 
 
 
The URL_STRING contains the information required to connect to a service, 
SERVICE_APPLICATION has information to identify the final result page from which the 
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results are extracted. The extraction rules consist of instructions read by the SIBIOS server in 
order to perform result extraction. The INTERFACE_PARAMETERS contain the input field 
description of the bioinformatics service. They can also contain optional parameters which 
may be used for additional specification of the input query to the service.  
 
2.5. Current Understanding 
 
Biomarker discovery is now becoming an essential and significant area of research. It has 
been proving vital in early cancer detection as well as diagnosis of tumors. Biomarkers are 
essentially a set of few genes (1, 2 or about 10 maximum), which serve as molecular 
signatures, that are in unwarranted amounts as compared to normal individuals. These genes 
(biomarkers) change the routine functioning of the human body by affecting the biological 
pathways. These genes if identified properly can be used in finding the root cause of cancers 
and therefore to develop drugs to target these genes to control their abnormal activity. 
Biomarkers are used to measure the progression of a disease, early warning signs of a 
disease, detection of disease recurrence, etc. It can also be used to determine which tumors 
respond to which treatments and predict the likelihood of drug resistance.  
 
This research provides an analysis of pediatric Acute Lymphoblastic Leukemia (ALL) whose 
gene expression data is available from the St Jude’s Website (M E Ross, 2003) and the 
procedure involved in discovering the biomarkers responsible for this disease. The protocol 
followed for this process is aided by SIBIOS and thus enhances the functionality of the 
system.  
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2.6. Problem statement and motivation  
 
The main problem today lies in the fact that there have been no set procedures to identify 
biomarkers for a given disease. This makes the process of adapting the SIBIOS workflow 
system a very difficult task especially when it comes to demonstrating its potential role in 
discovering biomarkers. 
 
Cancerous biomarkers can be effectively used for accurate evaluation and diagnosis of the 
disease in different stages as they serve as useful clinical indicators. In future they will guide 
physicians in every step of disease management. Thus it has been useful to work in this area 
and detect more and more biomarkers for different diseases.  
 
It is a challenge to develop sample protocols for the biomarker detection. Such a pipeline if 
proposed can be then utilized to automate the process of biomarker discovery through 
workflow based systems.  
 
So far, SIBIOS had been useful for carrying out various biological operations for different 
purposes such as gathering protein information, sequence matching, enzyme search etc. But 
recently with the onset of the genome project, it becomes important to integrate workflows 
for biomarker discoveries using microarray data. For this purpose it was needed to add new 
functionality to SIBIOS in order to support construction of complex workflows for cancer 
research. Such experiments involve analytical analyses and gene annotations.  
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2.7. Proposed solution 
 
There has been an extensive study on the existing microarray analysis approaches. All data 
analyses are quite powerful and robust in themselves. They highly depend on the data under 
study and its characteristics. The goal is to synthesize these techniques and propose sample 
protocols for biomarker discovery. These workflows need to be then tested and validated by 
analyzing the results. For this purpose a dataset is selected and used to validate the proposed 
protocol. The results are corroborated by performing biological annotations. Finally it is 
proposed to integrate the sample protocols which are converted into corresponding workflow 
which will make it feasible to incorporate it into SIBIOS.  
 
While each biomarker discovery analysis is context specific (e.g. for leukemia the gene 
expression level was studied for each subtype and the top distinguishing genes were found 
for each type (M E Ross, 2003)), the methodology that is proposed can be applied for other 
types of diseases in general. 
 
We propose to perform two experiments on the same dataset and study the results obtained 
by both approaches. One process involves the use of statistics and biological annotations as 
steps of the protocol developed for this biomarker discovery process. The other approach is a 
computational procedure which comprises of a series of recursive calculations to mine a set 
of interesting association rules specific to the type of cancer under study. It is the 
implementation of an algorithm called FARMER (G Cong, 2004). FARMER is basically a 
data mining procedure which generates interesting rules that are significant to a class of 
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samples. The results from both these approaches are then compared and analyzed for their 
biological relevance and significance. 
 
Every experiment is context specific so methodologies have been used corresponding to the 
leukemia cancer i.e. its form of occurrence, cells that it affects, clusters in which the subtypes 
occur, etc. 
 
The main goal of the experiment is to propose sample protocols and then use SIBIOS as a 
tool to support the construction of this workflow. To make SIBIOS more robust, 
bioinformatics services that perform analyses and gene annotations on input gene lists were 
added. These bioinformatics applications involved certain considerations that were needed to 
be facilitated by the system. In addition, SIBIOS capabilities need to be improved to take into 
account the characteristics of bioinformatics services used for biomarker discovery. 
 
The goal is not to propose one particular protocol for biomarker discovery but to characterize 
the main steps involved in this process, their objectives, and their importance and also 
involve the corresponding tools and databases.  
The outcome of this protocol is used  
 As a result by itself in proposing a list of potential biomarkers, supplied by good 
evidences from the available annotations of those genes. 
 As baseline developing templates of microarray workflows that will be used by 
researchers to build their own version of the workflow tailored to their data and 
disease in focus.        
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3. METHODS 
 
3.1. Gene expression and microarrays 
 
Gene expression can be used to understand the phenomenon related to the disease studied 
and microarrays allow the interrogation of thousands of genes at the same time. Two 
methodologies for biomarker discovery were adopted. These approaches are explained in 
detail in the next section. The initial dataset that was used to work on was a leukemia dataset 
(M E Ross, 2003).  
 
 3.2. Data Selection 
 
Here the objective of the research is to identify biomarkers specific to the subtype of the 
tumor, Acute Lymphoblastic Leukemia (ALL) in children. The dataset selected was a set of 
132 samples of children suffering from Acute Lymphoblastic Leukemia (ALL). This data set 
was selected based on the advantages that: 
 The microarray data was normalized. 
 The samples had signal intensities, detection call as well as p-values provided. 
 The data set was an Affymetrix data set on the chip HgU133A, that had more probe 
sets on it (around 22,000) compared to the previous Affymetrix chip, HgU95Av2 
having fewer probe sets in it (figure 12). 
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Figure 12: Comparison of the gene chips HgU133A and HgU95AV2 
 
This dataset has been very popular among various researchers also. HgU133A chip is used, 
because it can identify diagnostic discriminating genes from a larger portion of the human 
genome. It provides an almost threefold increase in the number of genes as compared to the 
previous chip, HgU95Av2. The data provides a large amount of information for the support 
of microarray-based expression profiling on a single platform for the detection of 
biomarkers of the known subtypes of pediatric ALL. 
 
3.3. Microarray Data Analysis 
 
Significant gene selection involves the process of mining relevant and meaningful genes 
from the initial dataset. Data mining can be defined as the extraction of previously unknown 
and potentially useful information from data. It is the science of extracting useful information 
from large datasets. The microarray dataset under study is on a HG-U133A chip. It contains 
expression values of specific mRNA levels. The data has been normalized and is for 132 
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patient samples from each of the leukemia subtypes. We devised two different approaches 
that give a good overview of the results. The purpose of analyzing the same dataset with two 
different approaches is to study how different methods affect the results obtained. The next 
step was to decide meaningful statistical computations to be applied on the dataset. The types 
of statistical tests applied, plays a major role in the results obtained. Studies applied on the 
same data having different results often used statistical techniques that are different in their 
approach. It is not always easy to choose statistical procedures to be applied. Each method 
has its own peculiar sensitivities and blind spots.  
 
There are two approaches that have been used here to accomplish the task of biomarker 
discovery analysis. The first approach is based on using analytical processes first and then 
applying annotations on the subset of gene lists. Two different methodologies have been 
applied here. One is based heavily on statistics for filtering data until a subset of genes are 
left for manual biological analysis. The second methodology is on the basis of a data mining 
algorithm that has been developed and implemented for mining significant genes from the 
microarray dataset. The aim of the algorithm was to generate interesting rule groups which 
help in identifying test samples as diseased or normal. These are association rules which are 
generated essentially from a set of genes that occur in a particular pattern specific to a group 
i.e. class or non-class. This algorithm is designed to mine the occurrence of specific genes 
whose occurrence indicates the presence or absence of the disease. Both these approaches are 
discussed in detail in section 3.3.1 and section 3.3.2. 
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      3.3.1. Analysis First-Annotation Second model 
 
This section describes in detail the two approaches that have been adopted to implement the 
process of significant gene selection. The purpose is to find an efficient way to the analysis in 
order to propose a small set of genes from the initial 22,000 probe sets. Section 3.3.1.1 
describes the statistical analysis procedure and section 3.3.1.2 describes the data mining 
algorithm. This method can also be called as a top-down approach. The basic flow diagram 
involved in this approach is shown in figure 13. 
 
Figure 13: Basic workflow of Analysis First Annotation Second Model 
 
This approach mainly uses gene analysis procedures first before using annotations on the 
subset of genes. The two methods implemented here were the statistical analysis procedure 
and the FARMER data mining algorithm. 
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3.3.1.1. Statistical Analysis Procedure 
       
Initially we have the gene data on the HG-U133A chips with its values of expression levels, 
detection call, and p-value. The goal is to identify biomarkers specific to each subtype of 
pediatric ALL. Initially the experiment was performed on one subtype i.e. BCR-ABL and 
later duplicated to each of the other subtypes to find significant genes specific to them. The 
protocol followed is the same for each subtype.  
 
From the analysis performed on several microarray studies, the following parameters have 
been identified to be used as a part of the process of filtering the most significant genes of 
interest. They are: 
 Detection Call 
 P-Value 
 Fold Change 
The procedures involved in obtaining these features and how they have been used in the 
filtering process have been described in detail below. 
 
Detection Call 
The detection call is the qualitative measurement indicating if a given transcript is detected 
(Present), not detected (Absent) or marginally detected (Marginal) in the sample. So our first 
step is to exclude the set of genes that are absent across all the patients. Extensive 
experiments were performed using Microsoft Excel. The other statistical analysis tools that 
were also incorporated for the microarray study were SpotFire (SpotFire, 1996), PAM (PAM, 
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2005), SAM (SAM, 2005), and Bioconductor (Bioconductor, 2001). There were a number of 
samples for each of the subtypes for ALL. The initial step was to label each gene of every 
sample within a subtype a representative detection call. This call was computed based on the 
occurrence of the call values across the samples of a particular probe set. The probe sets were 
given a call of ‘A’ if the number of presents across the samples were less than half the 
number of samples comprising the leukemia subgroup under analysis. (e.g. if in 12 samples a 
probe set X had less than 6 samples having a detection call of ‘P’, then probe set X was 
labeled ‘A’). If the samples had more than half the samples as ‘P’ then it was labeled a ‘P’ as 
the representative call for that probe set.  
 
The initial dataset had Affymetrix control sets and its signals. They were all removed prior to 
the analysis. For the study we had a group of diseased samples (E.g. BCR-ABL) called as 
class and non-diseased samples (E.g. non-BCR-ABL) called as non-class. Based on the 
detection calls for the class and the non-class probe sets we can see which of them are 
biologically interesting and which are not. A summary of the results is given in table 3. 
 
Table 3: Detection calls and interestingness measure 
Detection Calls 
Class Non-class 
Magnitude of 
class/non-class ratio 
Biological meaning Interesting 
gene 
M/A M/A Meaningless, can be 
anything 
The gene is probably not expressed in 
either condition 
No 
M/A P Meaningless, close to 
zero 
Gene expressed on the baseline array, 
not expressed in the experiment 
Yes 
P M/A Meaningless, very 
large 
Gene expressed on the experiment, not 
expressed in the baseline array 
Yes 
P P Meaningful, can be 
anything 
Gene expressed on both channels, 
useful ratio 
Depends on 
ratio 
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Fold Change 
A fold change is basically a measurement of the amount by which a probe set has been up-
regulated or down-regulated in a class compared to the probe set in the non-class. To 
compute the fold change, initially all expression values are converted to log2 based values 
(Lnm), as a log transformation generates an appropriate data range.  
Gnm = expression level of gene n in sample m 
n = (1 to 22,215) Number of probe ID 
m = (1 to 132) Number of samples 
Lnm = log 2 (Gnm)  
Based on these log transformed values, the fold change for every gene is calculated. While 
carrying out biomarker discovery, the two data sets that are studied are from normal samples 
(control) and from diseased (test) patients. The data sets are in pre processed states i.e. they 
have been scaled and normalized.  
 
For the fold change calculation, the average of the log transformed data from the control 
group is subtracted from the log transformed values of the test data. This difference is 
powered to 2, giving the fold change value result. Fold change signifies the amount of up or 
down regulation of a gene. E.g. fold change of 2 means an up-regulation of 2 fold and 0.5 
means a down-regulation of 2 fold.  
Lclass = Set of geometric average of log values of samples (class) across all probe IDs 
Lnon-class = Set of geometric average of log values of samples (non-class) across all probe IDs 
Dn = Lclass - Lnon-class 
FCn = 2 ^ Dn 
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FCn = Fold change of gene n in class compared to non-class 
 
P-Value 
P-value is the probability that a certain statistic is equal or more extreme to the observed 
value when the null hypothesis is true. The null hypothesis is that the two classes are the 
same. The p-values for the genes are calculated to quantify the significance of the 
differentially expressed genes. P-value helps in detecting significant genes present in the list, 
which are used further in the study for biological interpretation. A T-Test is carried out for 
this calculation. In order to apply a T-test it is necessary that the data has the samples as 
normally distributed as it is a parametric test. In order to see the distribution of the samples 
across each subtype, we plot their distributions to see the distribution of the microarray 
intensities. The log2 transformed expression values of the microarray data are plotted. It is 
commonly observed in biology that noise increases with the level. This problem is resolved 
by using transformations on the data. The most common transform is the logarithmic 
transform and it also has the attractive feature that fold changes of any given size appear as 
shifts of constant amounts for all genes. Figure 14 and 15 are the distributions of the subtypes 
BCR-ABL as well as T-ALL. All of the other subtypes showed a similar kind of distribution. 
The distributions of the intensities are roughly bell-shaped which indicate a nearly normal 
distribution of the samples. Therefore we can apply the T-test statistic to our data. 
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Figure 14: Roughly bell shaped distribution of BCR-ABL 
 
Figure 15: Nearly normal distribution of T-ALL subtype of Leukemia 
 
We want to consider up-regulated as well as down-regulated genes, so a 2-tailed T-test is 
performed. But as T-tests are used, the problem of false positives also arises. False positive is 
a Type I error and indicates that the gene has changed, but it actually has not. There needs to 
be a way to limit the number of false positives. If false positives are not tolerated then an 
approach involving the Bonferroni correction is employed. It means that if 100 T-tests are 
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performed then each p-value is multiplied by 100 to obtain the correct adjusted value. If the 
false positives can be tolerated then the use of False Discovery Rate (FDR) is incorporated. 
E.g. if a false positive rate of 15% can be tolerated, then the FDR is set to 0.15 and the p-
value is then calculated. FDR method is less conservative than Bonferroni and is usually 
more appropriate. This FDR method was implemented using a publicly available software 
and the p-value obtained was then used to set the threshold for filtering genes.  
 
Based on the calculations performed for detection call, P-value and fold change the probes 
are filtered based on certain specifications. Initially an excel file is created which contains the 
data for all probe IDs. There are columns containing log values of class group (BCR-ABL 
samples), log values of non-class group (non-BCR-ABL samples), detection call for class, 
detection call for non-class, difference of log values of class and non-class, fold change, and 
p-values. For instance, while working on significant genes specific to BCR-ABL class, and 
considering E2A-PBX1 as non-class, the corresponding excel file is shown in figure 16. 
 
Figure 16: Sample excel file for filtering 
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After construction of this dataset, the next step is to filter data based on certain thresholds. 
The data was filtered using the following criteria: 
a) Detection call P for class 
b) Detection call P for non-class 
c) Fold Change > 2.0 
d) P-value < 0.05 
 
Figure 17: Protocol followed for filtering significant genes 
 
After filtering process the data is substantially reduced and we are left with the set of genes 
that are significantly relevant towards the BCR-ABL subtype of Acute Lymphoblastic 
Leukemia. The entire protocol can be summarized as shown in figure 17. The same pipelined 
protocol was followed for each of the subtypes in order to obtain a set of genes specific to the 
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leukemia subtypes. The biological analyses were then done on this subset of genes using the 
SIBIOS system which will be explained later in chapter 4. 
 
After following this sample protocol a list of 108 genes were obtained which were used for 
biological analysis. After annotation those only 53 genes were uniquely identified and the 
rest were unclassified.  
 
3.3.1.2. Data mining using FARMER Algorithm 
 
This is the other approach that has been carried out for the purpose of obtaining a list of 
significant genes specific to a leukemic subtype. It is a data mining approach using 
FARMER algorithm. FARMER (G Cong, 2004) is an algorithm for Finding Interesting Rule 
Groups in Microarray Datasets. Interesting rules are the set of association rules generated 
from the same set of rows. Association rules are basically associations between different 
items in a dataset, corresponding to a particular class. In the context of microarray data, 
association rules can reveal biologically relevant associations between different genes. The 
items in the gene expression data can include genes that are highly expressed or represented, 
as well as relevant facts describing the biological process of the gene.  
Some of the advantageous features of the FARMER algorithm are: 
 It is adapted to microarray data where there are small number of rows and a large 
number of columns. 
 The generation of interesting groups is essentially a set of rules that are generated 
from the same set of rows.  
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 The process identifies a group of genes instead of individual genes that seem to have 
more biological support, in the sense that a group of genes are usually more 
responsible for an abnormality in the body.  
The algorithm is designed based on the condition that the dataset is oriented such that the 
rows are the samples and the columns contain the expression values of every gene ID. The 
advantage of working on such a dataset is that, interesting rules are generated from the same 
set of rows. These association rules are searched for row wise and as the size of the row 
enumeration space is much smaller than the size of the column enumeration space, the search 
time will be considerably lowered.  
 
Before applying the algorithm, a preprocessing phase is required to be carried out on the 
microarray data. This involves a process called as Entropy Discretization method (Entropy-
based-Discretization, 2002). Basically data mining algorithms work well on categorical data 
rather than on ordinal data. This preprocessing is done as a step to serve the purpose of data 
conversion. In addition FARMER, uses pruning strategies used to prevent unnecessary 
traversals of the enumeration tree that store the data. There are three strategies used here, 
which are described in detail in the later section.  
 
Adapting FARMER for biomarker discovery 
 
Recent studies have shown that association rules are very useful in detecting gene patterns of 
significant interest in microarray datasets (C Creighton, 2003). They can be potentially very 
useful in biological research. They are simple to interpret by biologists and can be easily 
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applied in scenarios like sample classification and significant gene pattern identification. 
These set of genes can be identified as potential biomarkers for a disease. Another advantage 
is that the process identifies a group of genes instead of individual genes which seems to 
have more biological support, in the sense that a group of genes might be biologically related 
to the disease and are collectively involved in the genetic pathway. 
 
The algorithm implemented here generates association rules of the form LHS → C, where 
LHS is the set of items and C is the class label. For our dataset we have used two class labels 
namely BCR-ABL class and non-BCR-ABL class. In order to obtain results, our 
methodology is based on certain thresholds of support and confidence. 
 ‘Support of X’ refers to the number of rows containing X in the dataset and is referred 
to as sup(X).  
 The probability of an association rule being true is called as the ‘confidence of the 
rule’. It is calculated as sup (LHS U C) / sup (LHS). So, ‘the support of the rule’ is 
the number of rows in the dataset that match the rule defined. 
In the domain of bioinformatics, there have been various algorithms that have been 
developed for mining association rules from microarray data. But they are generally 
computed over a column wise search space. This makes running such algorithms quite 
computationally expensive. If n is the maximum length of a row in the dataset, then the 
search space based on column enumeration could be as large as 2
n
. Column enumeration 
methods perform better when n<100, but when they are of the order of thousands, it makes 
such computations almost impractical. On the other hand, the number of rows in such 
datasets is generally of the order of hundreds to thousands. So if m is the number of rows, 
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then the size of the row enumeration search space is 2
m
. In the domain of microarray data 
sets, the size of row enumeration space is much less than the size of the column enumeration 
space. As a result it is more effective to devise an algorithm based on row enumeration.  
 
While mining for association rules, user-specified constraints such as minimum support (a 
statement of generality) and minimum confidence (a statement of predictive ability) are often 
imposed.  
 
In order to adapt FARMER algorithm to biomarker discovery, an implementation of the 
algorithm was necessary. Details of the implementation will be discussed later in this section. 
Before this step a data pre-processing step was performed on the initial dataset to be ready 
for the FARMER algorithm. 
 
Data Pre-processing 
Recall that the St Jude’s research data set (M E Ross, 2003) contains gene expression values 
of all 132 patients. We use the same dataset that we manipulated with the statistical based 
approach described in section 3.3.1.1. Our aim is to obtain interesting rule groups for each of 
the subtypes. The data pre-processing process involves three steps: 
1. Class Labeling 
2. Feature Reduction 
3. Feature Discretization 
These 3 steps are discussed in detail. 
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a) Class Labeling 
For the purpose of distinguishing each of the classes from each other, we label the samples 
under study accordingly. A sample is labeled by 1 to represent it as a class (e.g. BCR-ABL) 
and 0 to represent rest of the data as non class (e.g. non BCR-ABL) in the microarray data. 
 
b) Feature Reduction 
In order to run the algorithm on the microarray data, we first obtain a subset of genes from 
the initial list of 22,000 genes which are comparatively more significant than the rest of the 
genes. For this process of gene selection we use a software called PAM (Prediction Analysis 
for Microarrays). It is developed by a research group at the Stanford university (PAM, 2005). 
 
The set of significant genes obtained is based on the threshold that the user specifies.      
Typically one can try a number of different choices. In selecting the right choice, PAM does 
a K-fold cross validation for a range of threshold values. PAM was rum on a data set 
containing expression values of all 132 samples. Each of the six subtypes was labeled 
separately. As a result, on significant gene selection, a total of 88 genes were obtained with 
their corresponding scores listed with them at a threshold level of 10. These 88 genes were 
the genes that were significant across the entire 6 subtypes in the data set. The result of PAM 
is shown in figure 18. 
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Figure 18: Result from PAM containing score of each of the six subtypes for a set of 88 
significant genes. 
 
The next step was to obtain the expression values for each of the 88 genes across all of the 
132 samples. For every class an average expression value was calculated. This average taken 
was the geometric mean, in order to avoid the deviation of the actual mean across a set of 
samples due to the presence of any outliers. 
 
c) Feature Discretization 
A method was devised to categorize every expression value in every sample within a subtype 
based on its comparison with the average mean expression value. To carry out this process a 
method called as the entropy discretization method was incorporated. This method involves 
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the conversion of numeric value to a multi-interval discretization i.e. the conversion of 
numeric attributes to nominal (categorical) attributes.  
 
The process of gene expression transformation is based on the nearest shrunken centroid 
method. This method computes the standardized centroid for each class (R Tibshirani, 2002). 
This is the average of gene expressions for every gene in each class divided by the within-
class standard deviation for that gene. The nearest centroid classification takes the gene 
expression profile of a new sample and compares it to each of these class centroids. The class 
having the centroid closest to, in the squared distance, is the predicted class for that new 
sample. This shrinkage method is a good approach used for feature selection and has two 
advantages:  
1. By reducing the effect of noisy genes it can make the classifier more accurate. 
2. It does an automatic process of gene selection. 
Of the many ways for a fine-discretization approach, one of them is based on the heuristic of 
entropy minimization. Entropy based discretization involved the class entropy calculation. 
Here the geometric mean calculated with each subtype group serves as a cut point to 
discretize the data. The expression values of each sample are then compared to the geometric 
mean and based on the comparison an odd or even value is assigned. If the sample expression 
is lesser than the mean then an odd value is given else even. As a result we obtain a dataset 
containing values of attributes which are treated as categorical instead of numeric and are 
then fed into the mining algorithm to be processed.  
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Datasets for each of the 6 subtypes were prepared and then each of them were processed by 
the mining machine for computations.  
 
Mining Algorithm for association rule computation  
The data mining algorithm when applied on the dataset containing genes which were 
significant in comparison to the rest of the other genes, gives an output of association rules, 
based on a specified support and confidence.  
 
FARMER algorithm performs search by enumeration of row sets to find interesting rule 
groups with a specified consequent C. The entire data can be visualized as a enumeration tree 
of the row set from which interesting rules groups are searched for. The generation of this 
search tree is based on the successive comparisons of every row to the rest of the other rows 
present below it in the dataset. The result of each comparison is a set of items that are 
common to both the rows. This result becomes a child in the tree, of the first row node. The 
visual depiction of the FARMER search tree is given in figure 19. 
 
Figure 19: Generation of a row enumeration search tree from FARMER 
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After the construction of this tree structure, FARMER does a depth-first search on this 
enumeration tree by moving along its edges. The complete traversal of the row enumeration 
tree for mining interesting rules is not at all efficient. This is due to the fact that there are a 
lot of redundancies present in it, and we can avoid them by implementing some pruning 
strategies. Such pruning techniques snip off many unnecessary searches from the system 
making it more efficient and computationally economical.  
 
The formal algorithm involves many recursive computations of various nodes by carrying out 
a depth-first traversal of the row enumeration tree. There are three pruning strategies 
implemented in this algorithm, which is essential for the efficiency of this system. The 
emphasis is on the fact that the pruning steps do not clip off any interesting rules and rather 
prevent unnecessary traversals of the enumeration tree.  
 
Pruning Strategy 1 
This strategy is based on the fact that children nodes can deleted from the tree based on 
certain conditions. It can be visualized as if the child node is compressed to its parent node. 
For instance if a node has the item set (0, 3, 4) and its parent also has the same item set of (0, 
3, 4), then it is obvious that both the nodes will generate the same set of interesting rules. 
This redundancy can be achieved by pruning off the child node, so the search in the tree 
below that node is completely discarded. This saves search time considerably in the mining 
process.  
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Pruning Strategy 2 
This pruning strategy is implemented when an interesting rule has already been identified, 
and is discovered again later in the enumeration tree. The searching can be pruned below the 
node which is discovered later because it implies that any rules discovered at the descendants 
of that node, would have already been previously discovered.  
 
Pruning Strategy 3 
In this implementation search space is considerably reduced using the user specified 
thresholds of support and confidence. We calculate the upper bounds of these measures at 
every node for a sub tree rooted at a node X. If the estimated upper bound at X is below the 
user specified threshold, then we stop searching down the node X. A support threshold of for 
example 6 where the input dataset has 20 samples having leukemia would mean that the rule 
discovered should match at least 6 samples out of the given 20. These rule groups indicate a 
significant pattern involving interesting features in the leukemia dataset. Increasing the 
support makes the system generate better results but also puts more constraints on the system 
as more number of rows needs to match with the rule discovered. A confidence threshold of 
for example 97 % indicates the percentage of predictive ability of the system in mining such 
association rules. 
 
General steps of the FARMER algorithm are described below 
Algorithm 
1. Input ( Microarray data comprising of expression values and class labels, support, 
confidence) 
  67 
2. Generate a row wise enumeration tree that is a representation of the row sets to 
find interesting rule groups with a consequent, C. 
3. Traverse the tree for interesting rule groups with pruning strategies to prune of 
unnecessary searches: 
i. Pruning Strategy 1 
ii. Pruning Strategy 2 
iii. Pruning Strategy 3 
4. Result is a set of interesting rule groups. 
 
Interesting Rule Groups 
There were a number of interesting rules discovered from this system which indicated 
interesting patterns in the data set. For each data set of all the 6 subtypes, their respective 
interesting rule groups were obtained at various levels of support and confidence. The 6 data 
sets that were used had each two categories. The summary information is given in the table 3. 
 
Table 4: Datasets 
Dataset Class 1 Class 0 # rows 
BCR-ABL BCR Non-BCR 20 
E2A-PBX1 E2A Non-E2A 20 
HD50 HD50 Non-HD50 18 
MLL MLL Non-MLL 22 
TEL TEL Non-TEL 21 
T-ALL T-ALL Non-T-ALL 18 
 
The results obtained consist of a set of significant genes that make interesting rule groups. 
These set of genes specific to each subtype were analyzed in detail for their biological 
meaning. This was done by accessing various biological databases for their annotations, 
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pathways, disease involved, etc. To investigate the set of significant genes, SIBIOS system 
was adapted to aid in this research. Chapter 4 discusses more about the results obtained and 
how SIBIOS was used for the analysis of results. 
 
3.3.2 Annotation First-Analysis Second Model 
 
This is a novel approach recently proposed for the discovery of biomarkers. It is suggested 
that if the biology of the genes are taken into consideration during the filtering of the genes, 
then one can achieve better results from the analysis. Annotation term is the biological 
description of the gene function and can serve as useful information in filtering genes that are 
specific to a disease under study. The purpose of the model is to characterize the diseased 
patients based on the gene annotations. The method proposed by a research group in 
Germany (C Lottaz, 2005) falls in this category. They propose a new algorithm called StAM 
which takes into account the molecular information of the genes during the statistical 
analysis.  
  
Generally patterns discovered by the available methods of biomarker discovery are not 
focused from the biological perspective. Therefore the need arises to analyze genes using 
their underlying molecular disease mechanisms. Our purpose is to use association rules to 
discover annotation patterns specific to a disease compared to the normal tissue. These 
annotation patterns allow discovering potential biomarkers for the disease under study. Use 
of annotations help to filter genes based on their functional relevance to the gene. It is likely 
therefore to obtain more relevant genes that can serve as biomarkers using this approach. 
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Our method proposes to use GO (gene annotations) (GO, 1999) with FARMER algorithm to 
find interesting annotation-based rule groups. FARMER algorithm provides a set of 
association rules of the form LHS → C, where LHS in the new approach corresponds to a set 
of annotations. The set of annotations can be mapped to the corresponding genes and those 
genes can be marked as potential biomarkers. 
 
To apply the Annotation First-Analysis Second Model for extracting biomarkers we used the 
St Jude’s Dataset (M E Ross, 2003) which is same as the data set used for Analysis First-
Annotation Second Model. Recall that the dataset contained 132 samples and more than 
22,000 genes in it.  Before running the FARMER algorithm a set of pre-processing steps 
need to be applied to the microarray dataset. The initial microarray dataset consists of a set of 
samples of the diseased and non-diseased patients and their corresponding gene expression 
values.  
 
3.3.2.1. Data Pre-processing 
Before the FARMER algorithm could be applied to the data set a pre-processing phase needs 
to be performed. The steps can be classified as 5 stages: 
1. Class Labeling 
2. Feature Selection 
3. Feature Reduction 
4. Feature Transformation 
5. Feature Discretization 
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a) Class Labeling 
Sample datasets were classified as either part of BCR-ABL class (subtype of ALL marked as 
1) or of non-BCR-ABL class (marked as 0). 
 
b) Feature Selection 
As the purpose of this study is to identify potential biomarkers using annotations, for BCR-
ABL the aim of this step was to convert the dataset from gene identifiers to a list of 
annotation terms. Genes can be described with different biological annotations including 
gene ontology terms, protein-protein interactions and pathway information. In this study we 
consider only GO annotations. Different alternatives for annotations exist, varying from 
general to specific descriptions of the genes. Annotations provided by GO are hierarchically 
structured into 5 levels, varying from the most general (level 1) to the most specific (level 5). 
To map a given gene to its annotation we choose to consider the most specific annotation as 
well as their ancestors in the GO hierarchy. The relationships that exist between the genes 
and GO annotations is a many to many relationship (figure 20). In addition, many genes do 
not have any annotations; so they were unclassified.  
 
Figure 20: Many to many relationships between annotations (A) and genes (G) 
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At the end of feature selection phase a set of unique annotations are determined for each gene 
G. This set is denoted as A(G) hereafter. 
 
c) Feature Reduction 
The purpose of this step is to filter out unimportant annotations. We propose to determine the 
significance of the annotations of all the unique annotations based on the enrichment score of 
each annotation. The enrichment score is the number of genes that correspond to a particular 
annotation term. The annotations are then ranked according to the enrichment score in a 
descending order. A threshold for the enrichment score is set and then the top n annotations 
are retained as significant annotations. This set of significant annotations is used in the 
subsequent data pre-processing steps.  
 
d) Feature Transformation 
1. The objective of this step is to determine the gene expressions of each annotation for each 
data sample. For this purpose we use the gene expression associated to each gene 
annotation according to equation 1.  
                                        E(Ai)j = geometric mean (E(Gk)j)                                                  (1) 
i  (1 to n) ( where n is the number of annotations from the feature reduction step) 
k  ( 1 to m ) ( where m is the initial number of 22,000 genes) 
Ai  A (Gk)  
j is the sample number 
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E(Ai)j is called as expression of E(Ai) and E(Gk)j is the gene expression of gene k. The 
equation 1 calculates the geometric mean of the gene expressions over each sample Sj for 
each annotation Ai. 
For example if Ai maps to three genes G1, G2, and G3 (figure 21), then the value of E(Ai)j is 
the geometric mean of the gene expression levels G1, G2, and G3 for the sample Sj.          
 
Figure 21: Annotation mapping Ai to 3 genes 
 
Table 4 illustrates the sample dataset from the feature transformation phase. 
 
 Table 5: Sample data set from Feature Transformation 
Samples 
↓ 
Annotations
→ 
A1 A2     A3 A4 .
. 
.
. 
.
. 
.
. 
Ai 
S1 E(A1)1 E(A2)1 E(A3)1 E(A4)1 .
. 
.
. 
.
. 
.
. 
.. 
S2 E(A1)2 E(A2)2 E(A3)2 E(A4)2 .
. 
.
. 
.
. 
.
. 
.. 
.. … .. .. .. .
. 
.
. 
.
. 
.
. 
.. 
Sj E(A1)j E(A2)3 E(A3)j E(A4)j .
. 
.
. 
.
. 
.
. 
E(Ai)j 
 
e) Feature Discretization 
The purpose of this step is to categorize annotation expressions into two possible categories. 
 One category specifies that the annotation is differentially expressed 
 The second category specifies that the annotation is normally expressed 
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Recall that one of the categories is represented within FARMER by an even number and the 
other category is represented as an odd number. In order to perform categorization, we need 
to compare the expression of Ai (i.e. E(Ai)j ) to the geometric mean expression of Ai 
denoted as AE(Ai) over all samples. The geometric mean expression of the annotations over 
all the class and non-class samples (AE(Ai)) is calculated using equation 2. 
                                            AE(Ai) = geometric mean (E(Gk))                                             (2) 
i  (1 to n) where n is the number of genes from the feature reduction phase 
k  (1 to m) where m is the initial set of 22,000 genes 
 
In case E(Ai)j > AE(Ai) then a odd number is assigned to represent the pxpression of Ai for 
sample j otherwise an even number is selected. Table 5 illustrates the sample dataset obtained 
from the feature discretization pre-processing step. 
 
Table 6: Final Annotation data set 
Samples ↓ Annotations→ A1 A2 A3 A4 .. .. .. .. Ai 
S1 0 2 4 6 .. .. .. .. .. 
S2 1 2 5 7 .. .. .. .. .. 
.. … .. .. .. .. .. .. .. .. 
Sj  1 3 4 7 .. .. .. .. .. 
 
This discretization method is applied in order to distinguish the differentially expressed genes 
from the normally expressed genes.  
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Mining association rules using Annotation data set 
After this data preprocessing step we obtain a dataset of significant annotations and their 
categorical values for each sample. FARMER algorithm is then run on the resulting dataset. 
The algorithm generates a set of annotation patterns more precisely for rules presented as 
LHS → C. Annotations are the LHS part of the rule. The annotation patterns are mapped 
back to their corresponding genes. This subset of genes are then said to be the potential 
biomarkers for the disease that need to be validated for conclusive results. 
 
 
Figure 22: Workflow for Annotation First Annotation Second Model 
       
Figure 22 depicts the high level workflow of the main steps involved in this approach. The 
implementation of the proposed approach is yet to be carried out. These results obtained will 
be compared with the results obtained from the previous model i.e. Analysis First-Annotation 
Second Model. The objective is to find a list of potential biomarkers discovered from more 
than one approach. 
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The next step is to then study the issues related to adapting these models into the SIBIOS 
system.  
 
3.4. Adapting SIBIOS for biomarker discovery workflows 
 
The proposed Biomarker Discovery protocols involve bioinformatics services that perform 
data analysis as data annotations. The scope of this work is limited to the integration of 
annotation services.  
 
In order to incorporate the addition of annotation services and database tools that assist in 
biomarker discoveries, several changes were necessary to be performed on SIBIOS system. 
Some of the modifications have been made in the structure of the existing XML schemas for 
SIBIOS in order to accommodate the new services that have been incorporated into the 
system.  
 
3.4.1. Proposed Enhancements 
 
In this section we discuss the problems faced to adapt SIBIOS for biomarker discovery and 
the solutions proposed for them. 
1. SIBIOS did not include any annotation services. The database tools such as OMIM 
database are needed for the first model (Analysis First-Annotation Second Model) and 
annotation tools such as DAVID (DAVID, 2006) are required for the second model 
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(Annotation First-Analysis Second Model). The newly added biological tools to SIBIOS 
are:  
a. GO (Gene Ontology) (GO, 1999) for obtaining gene annotations such as 
biological processes, cellular functions and molecular functions. 
b. KEGG pathways (Kyoto Encyclopedia of Genes and Genomes) (KEGG, 1995) 
for obtaining regulatory pathways that the genes are involved in. 
c. DIP (Database of Interacting Proteins) (DIP, 1999) for retrieving experimentally 
determined interactions between proteins.  
The bioinformatics tools that were added to the SIBIOS were: 
a. GFinder (D Martucci, 2005) for finding gene annotations 
b. GOToolBox (GOToolBox, 2004) for computing p-values and enrichment levels 
of the genes id. It uses certain statistics for these computations. 
c. FuncAssociate (FuncAssociate, 2003) for finding annotations of the gene Ids. 
2. For the addition of these annotation tools, an issue related to session management was 
addressed. Integration of such services was possible if the session ID was maintained 
throughout the querying of the annotation tool using SIBIOS. To tackle this issue a 
modification was made in the structure of SIBIOS’s service schema. An additional tag 
called <ENTRY_URL> was added in the <URL_STRING> element. This field contained 
the URL of the initial homepage of the annotation service where the session value is 
assigned to an application. The purpose of adding this field is to allow SIBIOS to capture 
the session cookie for the service. The modification of the wrapper that interprets the 
service schema information was also performed. An example XML schema for a service 
called GFinder is given in the appendix. 
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3. The other issue related to annotation tools is the querying of large gene lists for their 
annotations. The gene lists can contain thousands of genes that need to be queried. Due to 
this the data needed to be queried becomes very large and cannot be sent through the 
conventional POST/GET http methods. The query needs to be written directly to the 
output stream as a sequence of bytes. For this purpose we added a tag <WRITE> to the 
XML schema where the query (e.g. gene lists) can be specified in this tag. An example of 
this tag is given in the appendix for the service GFinder. 
 
In the Results section the workflows designed in the SIBIOS system for gene explorations in 
the context of biomarker discovery are described.  
 
 
 
 
  78 
4. RESULTS 
In this section here we shall discuss the genes identified using our first approach for 
biomarker discovery. Their detailed analysis is done in section 4.1. In section 4.2 we shall 
discuss our workflow implementations in SIBIOS. In 4.3 the bioinformatics services added to 
the system are discussed. 
 
4.1. Results 
 
After the identification of the candidate genes by feature selection, it needs to be determined 
whether any of them are causal genes and if there are any surrogates. For this experiment we 
performed biological annotations and studied the gene regulatory pathways for each of the 
genes identified as significant. Genes are connected in a circuit or network. Expression of a 
gene in a network depends on the expression of some other genes in the network. It is then 
analyzed to determine if the genes affect other genes positively, negatively or in more 
complicated ways.  
 
A cancer cell can never express all the genes in a rule group in the same way with the same 
expression intensities. For this reason we observe each gene filtered out by the mining 
algorithm and analyze them in extreme detail. From the previous approach we got a list of 53 
unique genes and using the FARMER algorithm for BCR a set of 8 genes were identified to 
be significant. There were 3 genes were common in both the methods but we analyzed all 8 
in detail for the determination of biomarkers for ALL.  
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A general understanding in the process of cancer is that cell becomes incapable of normal 
differentiation. The search for the causation of leukemia has followed several approaches: 
infectious, genetic, physical and chemical. Over time it has become evident that all 
approaches may be correct and that several factors contribute for causing leukemia.  
 
A limited search was conducted to pick keywords related to leukemia such as apoptosis, 
chromosome abnormality, gene translocation, and poor DNA repair and tyrosine kinase 
inhibitor like terms were identified. 
 
This study focuses on BCR-ABL leukemia subtype. Studies show that BCR-ABL is 
associated with a more heterogeneous pattern of gene expression than the others. Also BCR-
ABL leukemias show relatively few consistent features in their expression patterns. This 
confirms the heterogeneous nature of this subtype. In BCR-ABL, enzymes that should 
regulate the growth and development of white blood cells go awry, resulting in uncontrolled 
growth of the cells. 
 
A chromosomal translocation creates the BCR-ABL genes and leads to expression of 
chimeric BCR-ABL protein with enhanced tyrosine kinase activity. This disrupts the basic 
cellular functions such as the control of proliferation, adherence to stroma and extracellular 
matrix and apoptosis.  
 
Mining for significant genes for BCR-ABL subtype gave 8 genes which can be potential 
biomarkers for this type of leukemia. The identified genes are: 
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1. Major histocompatibility complex, class II, DR alpha  
2. A kinase (PRKA) anchor protein 2  
3. Lymphoid-restricted membrane protein  
4. Protein tyrosine phosphatase type IV/A, member 2  
5. CD47 antigen (Rh-related antigen, integrin-associated signal transducer)  
6. Melanoma antigen, family D, 1 
7. Pre-B-cell leukemia transcription factor 1  
8. T cell receptor delta locus 
 
Description for each one of the listed above follows: 
 
Major histocompatibility complex, class II, DR alpha : 
The major histocompatibility complex (MHC) is a gene cluster of various loci grouped 
together at a single location. The MHC of humans, or the HLA complex, is located on the 
right arm of chromosome six approximately 32 cM from the centromere. The HLA complex 
in its entirety is more than 3800 kb. The loci of the HLA complex may be divided into three 
classes: Class I, Class II, and Class III. The products of Class I and Class II genes play an 
important role in the communication between cells. These MHC molecules are surface 
proteins which present antigenic peptides to T lymphocytes. The Class I and Class II genes 
exhibit a high degree of polymorphism. The genes are both multiallelic and multigenic. 
Class II genes are often referred to as immune response genes or IR genes (7). 
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The surface proteins produced by Class II genes are only present on specific types of cells 
known as antigen presenting cells (APC's). APC's include B lymphocytes, macrophages, and 
dendritic cells. These genes are shown in figure 23 and figure 24. 
 
Figure 23: HLA Complex 
 
 
Figure 24: Class I MHC genes, Class II MHC Genes 
MHC is said to have been involved in antigen dependent B cell activation and is a B 
lymphocyte cell surface molecule. Understanding these functions MHC can be further 
investigated to prove its association with leukemia. 
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A kinase (PRKA) anchor protein 2  
The A-kinase anchor proteins (AKAPs) are a group of structurally diverse proteins, which 
have the common function of binding to the regulatory subunit of protein kinase A (PKA) 
and confining the holoenzyme to discrete locations within the cell. This gene encodes a 
member of the AKAP family but its specific function has not been determined. This gene 
shares the same 5' exons with a separated gene PALM2 which encodes a protein implicated 
in plasma membrane dynamics. Alternative splicing of this gene results in several transcript 
variants encoding different isoforms, but the full-length nature of most variants has not been 
defined. 
The BCR-ABL gene formed by the mutation of the chromosomes 9 and 22 encodes tyrosine 
kinase which drives abnormal uncontrolled multiplication of leukemic cells. 
 
Lymphoid-restricted membrane protein  
The protein encoded by this gene is expressed in a developmentally regulated manner in 
lymphoid cell lines and tissues. The protein is localized to the cytoplasmic face of the 
endoplasmic reticulum. OMIM (OMIM, 1994) records have evidence for being one of the 
genes for cancer. 
 
Protein tyrosine phosphatase type IV/A, member 2  
The protein encoded by this gene belongs to a small class of prenylated protein tyrosine 
phosphatases (PTPs), which contains a PTP domain and a characteristic C-terminal 
prenylation motif. PTPs are cell signaling molecules that play regulatory roles in a variety of 
cellular processes. This tyrosine phosphatase is a nuclear protein, but may primarily associate 
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with plasma membrane. The surface membrane association of this protein depends on its C-
terminal prenylation. Overexpression of this gene in mammalian cells conferred a 
transformed phenotype, which implicated its role in the tumorigenesis. Studies in rat 
suggested that this gene may be an immediate-early gene in mitogen-stimulated cells. This 
process is involved in the process of leukemia as it is linked to the over regulation of tyrosine 
phosphatase. 
 
CD47 antigen (Rh-related antigen, integrin-associated signal transducer) 
This gene encodes a membrane protein, which is involved in the increase in intracellular 
calcium concentration that occurs upon cell adhesion to extracellular matrix. The encoded 
protein is also a receptor for the C-terminal cell binding domain of thrombospondin, and it 
may play a role in membrane transport and signal transduction. This gene has broad tissue 
distribution, and is reduced in expression on Rh erythrocytes. Four alternatively spliced 
transcript variants encoding distinct isoforms have been found for this gene. 
 
Melanoma antigen, family D, 1 
This gene is a member of the melanoma antigen gene (MAGE) family. Most of the genes of 
this family encode tumor specific antigens that are not expressed in normal adult tissues 
except testis. Although the protein encoded by this gene shares strong homology with 
members of the MAGE family, it is expressed in almost all normal adult tissues. This gene 
has been demonstrated to be involved in the p75 neurotrophin receptor mediated 
programmed cell death pathway. Three transcript variants encoding two different isoforms 
have been found for this gene. 
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Pre-B-cell leukemia transcription factor 1 
Human pre-B-cell acute lymphoblastic leukemias are frequently associated with a 
t(1;19)(q23;p13.3) chromosomal rearrangement. Kamps et al. (1990) and Nourse et al. 
(1990) demonstrated that several cell lines carrying this translocation synthesize chimeric 
mRNAs with 5’ sequences encoded by the E2A transcription factor gene (147141) on 
chromosome 19 and 3’ sequences encoded by a homeobox-related sequence, called Prl or 
PBX1, on chromosome 1. In the chimeric transcription factor, the DNA binding domain of 
E2A is replaced by a putative DNA binding domain of PBX1. In 3 cell lines reported by 
Nourse et al. (1990), identical E2A-Prl mRNA junctions were observed, suggesting that the 
fusion transcripts are a consistent feature of this translocation. 
 
T cell receptor delta locus 
Levels of T cell receptor delta gene arrangements serve as suitable markers of commitment 
of the lymphoid lineage. TCE delta rearrangements – most frequently found in B precursor 
acute lymphoblastic leukemia have been studied.  
 
With the study of all these genes we can confidently say that they are potential biomarkers of 
the leukemia disease. They affect the normal regulation of the body thereby causing 
leukemia. Below is a summary of all the genes investigated in table 7.  
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Table 7: Summary of 8 significant genes 
Affy 
ID 
Gene 
Name 
Cellular Molecular Biological Chromosome Gene Type SP Keyword 
212148
_at 
pre-B-
cell 
leukem
ia 
transcri
ption 
factor 1 
nucleus 
transcription 
factor 
activity 
regulation of 
transcription, 
DNA 
dependent 
19(LL), 1(LL) 
Gene with 
protein 
product, 
function 
known or 
inferred(ll) 
Chromosomal 
translocation, 
DNA-binding,  
nuclear protein, 
phosphorylation, 
proto-oncogene, 
transciption, 
transcription 
regulation, 
Acute 
lymphoblastic 
leukemia 
208616
_s_at 
protein 
tyrosin
e 
phosph
atase 
type 
IVA, 
membe
r 2 
cell 
membrane
, 
cytoplasm 
prenylated 
protein 
tyrosine  
phosphatase 
activity 
dephosphory
lation,  
macromolec
ule 
metabolism 
1(LL) 
Gene with 
protein 
product, 
function 
known or 
inferred(ll) 
Alternative 
splicing, 
hydrollase, 
lipoprotein, 
prenylation, 
protein 
phosphatase 
216988
_s_at 
protein 
tyrosin
e 
phosph
atase 
type 
IVA, 
membe
r 2 
cell 
membrane
, 
cytoplasm 
prenylated 
protein 
tyrosine  
phosphatase 
activity 
dephosphory
lation,  
macromolec
ule 
metabolism 
1(LL) 
Gene with 
protein 
product, 
function 
known or 
inferred(ll) 
Alternative 
splicing, 
hydrollase, 
lipoprotein, 
prenylation, 
protein 
phosphatase 
217143
_s_at 
T cell 
recepto
r delta 
locus 
   14(LL) 
Gene with 
protein 
product, 
demonstrates 
somatic 
rearrangeme
nt(ll) 
 
202759
_s_at 
A 
kinase 
(PRKA
) 
anchor 
protein 
2 
membrane  
regulation of 
cell shape 
9(LL) 
Gene with 
protein 
product, 
function 
known or 
inferred(ll) 
kinase, alternative 
splicing 
35974_
at 
lympho
id-
restrict
ed 
membr
ane 
protein 
endoplas
mic 
reticulum 
membrane 
 
hemocyte 
development 
12(LL) 
Gene with 
protein 
product, 
function 
known or 
inferred(ll) 
phosphorylation, 
endoplasmic 
reticulum 
211075
_s_at 
CD47 
antigen 
(Rh-
related 
antigen
, 
integrin
-
associa
ted 
signal 
transdu
cer) 
plasma 
membrane 
 
integrin 
mediated 
signalling 
pathway 
3(LL) 
Gene with 
protein 
product, 
function 
known or 
inferred(ll) 
Alternative 
splicing, cell 
adhesion, 
immunoglobin 
domain, 
transmembrane, 
signal 
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209014
_at 
melano
ma 
antigen
, family 
D, 1 
cytoplasm
, cell 
membrane 
 
involved in 
apoptotic 
response 
X(LL) 
Gene with 
protein 
product, 
function 
known or 
inferred(ll) 
Alternative 
splicing, repeat. 
208894
_at 
major 
histoco
mpatibi
lity 
comple
x, class 
II, DR 
alpha 
plasma 
membrane
, 
lysosome, 
plasma 
membrane 
MHC class II 
receptor 
activity 
Immune 
response 
6(LL) 
Gene with 
protein 
product, 
function 
known or 
inferred(ll) 
glycoprotein, 
immune response, 
MHC II, 
polymorphism, 
signal, 
transmembrane 
 
 
4.2 Gene Exploration using SIBIOS 
 
The advantage of using SIBIOS here is that we can work on multiple workflows and execute 
them in parallel. These results can be compared with each other to provide a broad picture of 
the genes under study. In addition, by undertaking several data analyses one might point out 
certain peculiarities in the genes which might indicate a potential discovery.  
 
There are various online web applications which are very powerful and do diverse 
computations. It is very advantageous to exploit these applications and use them for 
biological analyses on a common platform. The issue of heterogeneity can be easily tackled; 
saving considerable time for the researchers. Many biologists themselves are not aware of the 
various formats and the conversions required in order to work with such gene lists.  
 
4.3. Analysis of results in SIBIOS  
 
Our first group of genes under study was a set of 9 genes for BCR which were explored using 
the SIBIOS system. 
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Shown in figure 25 is the workflow that has been constructed which executes two separate 
analyses on the same set of genes.  
 
Figure 25: Workflow for analyzing microarray genes for biomarker discovery 
 
The first workflow is of the web application GFinder (D Martucci, 2005). GFinder is a web 
tool that enables to better understand microarray experiment results and mine knowledge by 
examining user sequence ID lists or gene lists. It also applies certain clustering and statistical 
methods on the genomic annotations from several databases to better understand the input 
list. It has two modules i.e. the gene annotation module and the pathway exploration module. 
The annotations provide are gene symbol, cytogenetic location, Entrez gene ID, GO category 
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and disease category. In the pathway exploration module the biochemical pathway 
information is available to the user from the SIBIOS platform.  
 
The second workflow involves the web application GOToolBox (GOToolBox, 2004). This 
service works on a data set which is generated by its own server, so it is necessary to 
generate a format which is acceptable to GOToolBox. This process is carried out by the first 
module in the workflow. The file information is then sent to the next modules i.e. GO-Stat 
and GO-Proxy. These two modules analyze the input gene lists using some statistical 
approaches which can be selected by the user. The GO-Stat module points statistically over 
or under represented terms within the input dataset. The statistical tests provided are Fisher 
exact test, Binomial-based probability calculations as well as Bonferroni correction for 
multiple testing. The analysis of enrichment or depletion of the input gene terms can be done 
with GO-Stat. The p-value correction can be done using the Bonferroni correction option. In 
the GO-Proxy module, clustering of genes is done based on the GO annotations. The 
distances between pairs of genes are calculated using the Czekanowsky-Dice formula. The 
distance matrix is then processed using a clustering algorithm, and then the resultant tree is 
then portioned given user-defined class attributes.  
 
SIBIOS has therefore been adapted to assist the process of biomarker discovery. The models 
that had been provided above can be used as templates to be incorporated into SIBIOS. The 
capabilities to provide such protocols have been developed. Currently we have a partial 
template adapted to SIBIOS. The main challenge faced while adapting microarray 
experiments completely to SIBIOS is the issue to integrate stand alone tools. There are 
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various stand alone applications that provide various capabilities which need to be exploited 
by integrating such tools.  
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5. CONCLUSION 
5.1. Conclusion 
In this research, sample protocols for microarray analysis in the context of biomarker 
discovery has been designed, implemented and deployed. There have been two concepts that 
were proposed i.e. 
1. Analysis First-Annotation Second model 
2. Annotation First-Analysis Second model 
The first model had two approaches i.e. the statistical analysis and the data mining method 
that has been studied and implemented. The framework for the second model has been 
designed and needs to be implemented. The protocols that have been devised for the purpose 
of biomarker discovery are useful in the following ways: 
 
1. They provide a framework for conducting different experiments related to the 
identification of biomarkers. 
2. The results of applying some of the protocols provide with a list of candidate biomarkers. 
3. SIBIOS has been provided with a framework for facilitating a workflow for microarray 
analysis experiments. This provides a platform for efficient and time-saving research 
approach to biological researchers. 
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5.2. Future Work  
 
The future work for this research area can be divided into two parts: 
1. There has been a framework developed for Annotation first and Analysis Second module. 
This approach needs to be implemented and validated for its results.  
2. The full implementation of the proposed protocols needs to be carried out within the 
SIBIOS system. This will necessitate the integration of bioinformatics services that 
implement statistical computations which form a part of microarray analysis. 
3.  An enhancement needs to be made in SIBIOS where it can incorporate the addition of 
standalone services. There are various efficient and resourceful applications for 
microarray applications like Genesis (Genesis, 2006) and Bioconductor (Bioconductor, 
2001). They perform many statistical computations and are very helpful for significant 
gene selection in the context of biomarker discovery.   
 
5.3. Summary 
 
The aim of this research was to propose SIBIOS workflow integration system as a design 
environment for building in-silico experiments for biomarker discovery. To undertake this 
task, a deep understanding of the current procedures followed by researchers to extract the 
most biologically significant genes was paramount to this study.  
 
In the course of validation of the proposed protocols, a case study on the BCR subtype of 
ALL was selected. 
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During the course of this research there were various details that were important to 
understand in the microarray analysis. They were needed to be studied and were not 
described in the published work of the researchers. They were subjective decisions that were 
taken during the filtering process; and that by moving to a standard procedure less 
subjectivity will exist in the process. 
 
This thesis has led to the identification of potential biomarkers for pediatric Acute 
Lymphoblastic Leukemia. A framework has been provided on SIBIOS that assists in the 
design and deployment of workflows based on the integration of applications which work on 
microarray data.  
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APPENDIX  
XML Schema for GFinder annotation service demonstrating the <ENTRY_URL> tag. 
   <?xml version="1.0" encoding="ISO88591" standalone="yes" ?>  
  <TOP> 
  <SERVICE_APPLICATION> 
   <SERVICE_NAME>gfinder_cookie_service</SERVICE_NAME>  
  <PATH_PAGE> 
   <PAGE_CHARACTER>{title}uploaded gene list</PAGE_CHARACTER>  
   <EXTRACT_LINK>sh='{title' t='title}' l='}' r='{'</EXTRACT_LINK>  
   </PATH_PAGE> 
   </SERVICE_APPLICATION> 
  <URL_STRING> 
   <SINGLE_QUERY> 
    <BASIC_URL>http://promoter.bioing.polimi.it/gfinder/eng/abc_process.asp</BASIC_URL>  
<METHOD>P</METHOD>  
    <UPLOAD>filename=XXXX</UPLOAD>  
    <WRITE>null</WRITE>  
    <ENTRY_URL>http://promoter.bioing.polimi.it/gfinder/default.asp</ENTRY_URL>  
    <DEFAULT_PARAMETERS />  
    </SINGLE_QUERY> 
   </URL_STRING> 
 <EXTRACTION_RULES> 
<FILECODE>sh='input name="file"' t='input name="estensione"' l='value="' 
r='"}'</FILECODE>  
<EXP_NO>sh='{input name="esperimento" type="hidden" id="esperimento"' t='}' l='value="' 
r='"'</EXP_NO>  
<CEXP_NO>sh='{input name="esperimento" type="hidden" id="esperimento"' t='}' 
l='value="' r='"'</CEXP_NO>  
<COOKIE1>null</COOKIE1>  
</EXTRACTION_RULES> 
<INTERFACE_PARAMETERS> 
  <MAN_OR> 
  <PARAMETER> 
   <NAME>UPLOAD</NAME>  
   <DESCRIPTION>File Name Location</DESCRIPTION>  
  <TYPE> 
   <UPLOAD_FILE />  
   </TYPE> 
 <DEFAULT_VALUE />  
 </PARAMETER> 
   </MAN_OR> 
   </INTERFACE_PARAMETERS> 
 </TOP> 
 
 
XML Schema for GFinder annotation service demonstrating the <WRITE> tag. 
   <?xml version="1.0" encoding="ISO88591" standalone="yes" ?>  
  <TOP> 
  <SERVICE_APPLICATION> 
   <SERVICE_NAME>gfinder_annotation_service</SERVICE_NAME>  
  <PATH_PAGE> 
   <PAGE_CHARACTER>{title}annotation</PAGE_CHARACTER>  
   <EXTRACT_LINK>sh='{title' t='/title}' l='}' r='{'</EXTRACT_LINK>  
   </PATH_PAGE> 
   </SERVICE_APPLICATION> 
  <URL_STRING> 
  <SINGLE_QUERY> 
   <BASIC_URL>http://promoter.bioing.polimi.it/gfinder/eng/gesesperimenti2.asp</BASIC_URL>  
   <METHOD>P</METHOD>  
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   <ENTRY_URL>null</ENTRY_URL>  
       <WRITE>vistempo=1!livello=!soglia=!Submit=Execute!nodo=!nomenodo=!ontologia=!classe=!t
 empo=!numrighe=!numrighetot=!ordina=!maggmin=!reload=!phenotype=!bg=undefined!nuov
 afin=undefined!risultati=undefined!Y1=undefined!Y0=undefined!lev=undefined!conta=undefin
 ed!colonna=undefined!test=undefined!calcola=undefined!sottoclassi=undefined!distance=und
 efined!nome=undefined!tabella=undefined!numcolonne=undefined!tabtemp=undefined!nomee
 sperimento=undefined!colonneregolaz=undefined!ID=undefined!chip=undefined!llid=undefine
 d!accno=undefined!pfam=undefined!nomepfam=undefined!cod=undefined!kegg=undefined!pa
 thway=undefined!versione=undefined!numcategorie=undefined!cominciada=undefined!radiob
 utton=Visualizza!cutoff=undefined!tuttioannotati=undefined!nolistapredef=undefined!listapre
 def=undefined!maxrighe=undefined!evidence=undefined!specie=undefined!speciepresente=u
 ndefined!minIDs=undefined!conversione=undefined!conversionepresente=undefined!poolcate
 g=undefined!finestragrande=undefined!rappresentate=undefined!sogliaR=undefined!correzion
 e=undefined!viscolonna0=undefined!colonna0=1!ordinacol0=ASC!viscolonna1=si!colonna1=2!
 ordinacol1=ASC!viscolonna2=si!colonna2=3!ordinacol2=ASC!viscolonna3=si!colonna3=4!ordin
 acol3=ASC!viscolonna4=undefined!colonna4=5!ordinacol4=ASC!viscolonna5=undefined!colonn
 a5=6!ordinacol5=ASC!viscolonna6=undefined!colonna6=7!ordinacol6=ASC!viscolonna7=undefi
 ned!colonna7=8!ordinacol7=ASC!viscolonna8=undefined!colonna8=9!ordinacol8=ASC!viscolon
 na9=undefined!colonna9=10!ordinacol9=ASC!viscolonna10=undefined!colonna10=11!ordinaco
 l10=ASC!viscolonna11=undefined!colonna11=12!ordinacol11=ASC!viscolonna12=undefined!co
 lonna12=13!ordinacol12=ASC!viscolonna13=undefined!colonna13=14!ordinacol13=ASC!viscol
 onna14=undefined!colonna14=15!ordinacol14=ASC!viscolonna15=undefined!colonna15=16!or
 dinacol15=ASC!viscolonna16=undefined!colonna16=17!ordinacol16=ASC!viscolonna17=undefi
 ned!colonna17=18!ordinacol17=ASC</WRITE>  
   <DEFAULT_PARAMETERS />  
   <GENE_NAME>viscolonna1=XXXX</GENE_NAME>  
   <GENE_SYMBOL>viscolonna2=XXXX</GENE_SYMBOL>  
   <EXP_NO>esperimento=XXXX</EXP_NO>  
   <CEXP_NO>codesperimento=XXXX!esperimento=XXXX</CEXP_NO>  
   </SINGLE_QUERY> 
   </URL_STRING> 
  <EXTRACTION_RULES> 
  <ANNOTATION> 
   gh='{table class="normale" width="1%" border="1" align="center"}' t='{/table}' s='{tr'  
   <SEQUENCE_ID>sh='{td' t='!nbsp;{/td}' l='}' r='!nbsp;{/td}'</SEQUENCE_ID>  
   <GENE_NAME>sh='(http://ihome.cuhk.edu.hk/~b400559/array.html#Hardware)' t='!nbsp;{/td}' 
 l='}' r='!nbsp;{/td}'</GENE_NAME>  
  <GENE_SYMBOL>sh='a target' t='!nbsp;{/td}' l='}' 
 r='(http://ihome.cuhk.edu.hk/~b400559/array.html#Hardware)'</GENE_SYMBOL>  
   </ANNOTATION> 
   </EXTRACTION_RULES> 
    
  <INTERFACE_PARAMETERS> 
     
  <MAN_OR> 
    
  <PARAMETER> 
   <NAME>GENE_NAME</NAME>  
   <DESCRIPTION>Gene Name</DESCRIPTION>  
     
  <TYPE> 
  <TEXTAREA> 
  <CHOICE> 
   <VALUE>si</VALUE>  
   </CHOICE> 
   </TEXTAREA> 
   </TYPE> 
   <DEFAULT_VALUE />  
   </PARAMETER> 
  <PARAMETER> 
   <NAME>EXP_NO</NAME>  
   <DESCRIPTION>exp Name</DESCRIPTION>  
    
  <TYPE> 
  <TEXTAREA> 
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  <CHOICE> 
   <VALUE>si</VALUE>  
   </CHOICE> 
   </TEXTAREA> 
   </TYPE> 
   <DEFAULT_VALUE />  
   </PARAMETER> 
  <PARAMETER> 
   <NAME>CEXP_NO</NAME>  
   <DESCRIPTION>cexp Name</DESCRIPTION>  
    
  <TYPE> 
  <TEXTAREA> 
  <CHOICE> 
   <VALUE>si</VALUE>  
  </CHOICE> 
  </TEXTAREA> 
  </TYPE> 
   <DEFAULT_VALUE />  
  </PARAMETER> 
  </MAN_OR> 
  </INTERFACE_PARAMETERS> 
  </TOP> 
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CURRICULUM VITAE 
Bhavna Choudhury, bchoudhu@iupui.com (317-341-5874),  
319 N West St, # 339, Indianapolis, IN 46202__________________________________ 
 
OBJECTIVE 
A full time position in the discipline of software development with major responsibilities that will 
effectively utilize my technical, leadership and organizational skills.  
 
SUMMARY  
• Experienced in development of both front-end and back-end applications using Java 2, JSP 1.2, 
Java Script, JDBC, XML and HTML.  
• Expertise in Object Oriented Programming and Relational Databases. 
• Experienced in working with Relational Databases like Oracle 9i/8i and MS Access. 
• Experienced in coding Stored Procedures, Functions, Packages and Triggers using PL/SQL. 
• Experienced in working with Application and Web Servers Apache Tomcat 4.1/5.1. 
• Knowledge of writing AJAX (Asynchronous Java Script and XML) pages. 
• Extensive knowledge working with IDE tools like Eclipse 3.1.  
• Experienced in requirement gathering, prototype designing and documentation.  
• Good understanding in Software Life cycle phases like Feasibility, System studies, Design, 
Coding, Testing, Debugging, implementation and Maintenance. 
• Good analytical skills and the determination to solve problems. 
• Excellent English verbal and written communication skills. 
• Dependable and reliable in supporting and enabling team effort. 
 
EDUCATION 
MS : Bioinformatics, Indiana University Purdue University Indianapolis, (Aug 2004 - June 2006)  
BS : Computer Science, JSS Academy of Technical Education, Noida, (Sep 2000 - May 2004) 
 
 
PROFESSIONAL SKILLS 
Languages  Java , C, C++, Perl 
Technologies  J2SE 1.4, J2EE 1.4, JSP1.2, RMI, JDBC, XML, SAX, JAXP, XQuery, XPath 
Web Server  Tomcat 4.1/5.1 
Data Bases  Oracle 9i/8i and MS Access, SQL Server, SQL Loader, PL/SQL 
Operating Systems Windows based (2000, 9x, NT) , UNIX, MS-DOS 
Scripting Language HTML, Java Script, MS FrontPage 
Tools     Eclipse, ANT, MATLAB 7, SPSS, Spotfire 
Office Tools  MS- Word/Excel/PowerPoint/FrontPage 
Biological Database Swiss-Prot, Protein Data Bank, GeneBank, ENBL, GO, DIP, OMIM, NCBI  
Course work  Computer Networks, Analysis and Design of Networks, Biostatistics 
 
WORK EXPERIENCE/ PROJECTS UNDERTAKEN 
 
Institution:Indiana University Purdue University Indianapolis, IN        Jan 2005 – June 2006 
Project: System for Integration of Bioinformatics Services (SIBIOS) 
Role: Java Developer 
SIBIOS is an application designed to facilitate biological workflows for researchers. This application 
utilizes the web applications which become modules of the workflow. A reasoning system is provided by 
an ontology. It is based on the protocol that involves making http connections with the web applications 
and extract results through these remote applications. These results are then provided on the SIBIOS 
platform 
Responsibilities: 
• Involved in requirement gathering and designing the flow. 
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• Engineered SIBIOS to enable researchers with a generic framework to work on in-silico 
experiments in biomarker discovery  
• Used  Eclipse 3.1 as the IDE tool for developing different modules. 
• Developed the module to maintain sessions of bioinformatics applications through SIBIOS. 
• Used ANT tool for creating and deploying the .jar files for the system 
Environment: Eclipse 3.1, J2SE1.4, HTML, XML 
 
Institution:Indiana University Purdue University Indianapolis, IN         Jan 2006 – May 2006 
Project: FARMER (Data Mining Algorithm for microarray datasets) 
Role: Java programmer 
This is an application that mines interesting association rules from the microarray datasets that discovers 
significant gene patterns indicating the presence of cancer or not in a patient.  
Responsibilities: 
• Built a java based application that finds interesting rule groups from a microarray dataset based on 
the FARMER algorithm.    
• Did mining of association rules which help in Biomarker detection from Microarray datasets based 
on the gene expression intensities. 
Environment: Eclipse 3.1, J2SE1.5 
 
Institution:Indiana University Purdue University Indianapolis         Jan 2006 – May 2006                                                 
Project: Integrated MicroArray Gene Explorer (IMAGE) 
Role: Java/J2EE developer 
This tool was developed to maintain microarray experiments and query biological databases to obtain 
various information related to the significant genes of interest. 
Responsibilities: 
• Developed a tool in java for microarray data analysis for gene annotation using public databases. 
• The tool helps in analyzing data for gene expression levels for information on diseases, associated 
proteins, etc. 
• Used Eclipse Java IDE tool for creating JSPs and XML. 
• Involved in JDBC coding for establishing connection with the database and connecting to MS 
Excel documents. 
Environment: J2SE1.2,JSP, JDBC, JavaScript, Oracle 10g, XML, SAX 
 
Institution:Indiana University Purdue University Indianapolis         Aug 2005 – Dec 2005 
Project: Image Search Engine 
Role: Java programmer 
Developed a system that searches for images from online PDF papers and journals in the biological 
domain. User inputs a query in the form of gene names or protein IDs and retrieves papers based on such 
queries and gives the image on the result page. 
Responsibilities: 
• Designed database tables using Oracle 10g which contained BLOB type of data to store images as 
a bitmap. 
• Involved in JDBC coding for establishing connection with the database 
• Developed Perl scripts using the LWP module to download mass PDF documents from a website 
together. 
• Involved in deployment of the application in Tomcat server 
Environment: J2SE1.2,JSP, JDBC, Oracle 10g 
     
Institution:Indiana University Purdue University Indianapolis         Jan 2005 – May 2005 
Project: Informatics Faculty Search System 
Role: Java programmer 
Responsibilities: 
• Built a faculty search system for the entire faculty of the Indiana School of Informatics. 
• The user could search courses provided by the faculty, his research interests, etc. 
• Developed the module to create and edit profile of faculties.  
Environment: J2SE1.2,JSP, JDBC, JavaScript, Oracle 9i   
